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1General introduction and 
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General introduction 11
Since the 1970s group B Streptococcus (GBS) has been recognized as the leading 
cause of severe neonatal early-onset infection. Neonatal early-onset GBS infection can 
be prevented by intrapartum antibiotic prophylaxis in women who are at increased 
risk for transmitting the infection to their newborn. In the USA the Center for Disease 
Control and Prevention recommended in 1996 prevention guidelines based on either 
one of two strategies.1 The fi rst strategy was based on universal screening for vaginal 
and rectal colonization of all pregnant women at 35-37 weeks gestation and the second 
strategy was based on the presence of one of the following fi ve risk factors at the time of 
labour: preterm onset of labour (<37 weeks), prolonged rupture of membranes (>18 h), 
intrapartum fever (> 38°C), GBS bacteriuria during the current pregnancy and a previous 
delivery of an infant with serious GBS disease. The effectiveness of these guidelines was 
demonstrated. In selected areas in the USA, the incidence of proven neonatal early-onset 
GBS sepsis decreased from 1.7 per 1000 live births in 1993 to 0.6 per 1000 live births in 
1998. 2 Little published data were available on the incidence of early-onset GBS disease 
in European countries and strategies for prevention of early-onset GBS disease in Europe 
were developed later than in the USA. In 1998, the Dutch Paediatric Association and the 
Dutch Society of Obstetrics and Gynaecology introduced guidelines for prevention of 
early-onset GBS disease. These guidelines are based on the risk factor based strategy as 
recommended in the USA in 1996 as one of two possible strategies. In chapter 2 these 
Dutch guidelines will be discussed. 
The aims of this thesis were: 
1. To get more insight in the incidence of neonatal GBS disease and the existence of 
prevention strategies in different countries in Europe (chapter 3)
From Europe only limited data about maternal GBS colonisation and the incidence of 
neonatal GBS disease were available. It was not clear in how many European countries 
a nationwide prevention strategy for neonatal GBS disease has been developed already. 
Therefore, we sent a questionnaire to all members of the European Society for Paediatric 
Infectious Diseases and to all national delegates of the European Association of Perinatal 
Medicine.
2. To investigate the epidemiology of neonatal GBS disease before and after the 
introduction of the Dutch guidelines for prevention of early-onset GBS disease (chapters 4 
and 5)
In the Netherlands no nationwide data on the incidence of neonatal GBS disease were 
available. First, we collected data of all infants with GBS disease during the fi rst 3 months 
of life, as reported to the Dutch Paediatric Surveillance Unit (DPSU) during a period 
of two years (1997-1998) before the introduction of the Dutch guidelines. Neonates 
with early-onset GBS disease were categorised as having proven sepsis or probable 
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sepsis. Proven sepsis was defi ned by the simultaneous presence of clinical features of 
septicaemia, abnormal results of laboratory investigations as well as a positive culture 
of blood and/or cerebrospinal fl uid. Probable sepsis was defi ned by the presence of the 
same clinical and laboratory features and the isolation of GBS from various sites, but 
without a positive blood and/or CSF culture. We collected data of patients with probable 
sepsis as well. After the introduction of the Dutch prevention guidelines in 1999 we 
decided to collect the same data of all infants with GBS disease (proven and probable 
sepsis) during the fi rst 3 months of life in 1999-2001. We compared the periods before 
(1997-1998) and after (1999-2001) the introduction of these guidelines.
3. To investigate the compliance of Dutch obstetricians with the guidelines for prevention 
of early-onset GBS disease after the introduction in 1999 
(chapter 6)
To be able to evaluate whether a change in incidence in GBS-disease could be attributed 
to a change in the application of antibiotic prophylaxis, we performed a survey among 
obstetricians on the existence of and familiarity with prevention protocols as well as the 
adherence to them, both in 1997 and in 2000.
4. To investigate the distribution of the different serotypes, genotypes and changes in 
antibiotic susceptibility before and after the introduction of the guidelines (chapter 7) 
We studied the characteristics of strains isolated from neonates with GBS sepsis and 
meningitis both before (1997-1998) and after (1999) the introduction of the guidelines for 
prevention of neonatal GBS disease. Serotyping, genotyping and susceptibility testing of 
the GBS strains were performed. 
 
The overall aim of this thesis was to establish the scientifi c information needed in order to 
improve the measures for prevention of neonatal GBS disease. 
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Abstract 
Early-onset group B streptococcal (GBS) infection can be prevented by intrapartum 
antibiotic prophylaxis. In the USA the effectiveness of this strategy was demonstrated after 
the introduction of formal guidelines in 1996. In Europe prevention strategies for early-
onset GBS-infection have not been implemented universally. In 1998 the Dutch Society 
of Paediatrics and the Dutch Society of Obstetrics and Gynaecology posted conjoint 
guidelines for the prevention of early-onset GBS disease based on currently available 
knowledge and local situation. These guidelines will be discussed in this overview.
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Introduction 
Since the 1970s Group B Streptococcus (GBS; Streptococcus agalactiae) has been 
recognised as the leading cause of serious neonatal infection. Early-onset GBS infection 
can be prevented in the majority of cases by intrapartum antibiotic prophylaxis in women 
who are at increased risk for transmitting the infection to their newborn. In the USA the 
effectiveness of intrapartum antibiotic prophylaxis as a prevention strategy for early-onset 
GBS disease was demonstrated after the introduction of formal guidelines in 1996. 1,2 In a 
recent study it was shown that the incidence of proven neonatal early-onset GBS-sepsis 
in the USA decreased from 1.7 per 1000 live births in 1993 to 0.6 per 1000 live births in 
1998. 3 In Europe there are little published data on nation-wide incidences of early-onset 
GBS disease and prevention strategies for this disease have not been implemented 
universally. In the Netherlands we studied the nationwide incidence of neonatal GBS 
disease during a 2-year period (1997-1998). We showed that the nationwide overall 
incidence of early-onset GBS-disease (sepsis and probable sepsis) in the Netherlands 
in 1997-1998 was about 1.9 per 1000 live births. The incidence of proven neonatal 
early-onset GBS-sepsis alone was 0.6 per 1000 live births. 4 In the meantime the Dutch 
Society of Paediatrics and the Dutch Society of Obstetrics and Gynaecology posted 
conjoint guidelines for prevention of early-onset GBS disease in the Netherlands based on 
currently available knowledge and the local situation. 
Background
GBS are facultative anaerobic Gram-positive streptococci that, on blood agar, cause 
a characteristic zone of β-haemolysis around colonies. Some strains do not cause 
haemolysis or cause α-haemolysis. With serological techniques using capsular 
polysaccharides as type-specifi c antigens and surface proteins as additional antigenic 
markers, GBS can be distinguished from other serotypes (A,C,D and G) and divided into 
seven subtypes (Ia, Ib, II, III, IV, V and VI). GBS disease is caused mainly by serotypes I, 
II and III. 5
GBS easily colonizes the urogenital tract from the gut; the carrier state may be temporary, 
intermittent or persistent. The predictive value of antenatal cultures for carriage at birth 
has a reciprocal relationship with the interval between diagnosis and delivery. So, 
cultures taken after 35 weeks have a negative predictive value of 97% and a positive 
predictive value of 89% for GBS carriage at the time of birth. 6 Asymptomatic colonization 
with GBS can be found in 10-30% of all pregnant women, depending on the population 
studied, number of sites cultured and the method of culture. In the Netherlands the 
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percentage of GBS-carriers is between 15 and 20%.7 About 50% of infants of GBS-carriers 
will be colonized through vertical transmission at birth. Persistent carriage and high-level 
maternal colonization are important risk factors for perinatal transmission. 8 The serotypes 
of GBS found in carriers are similar to those in their colonized infants. Of the colonized 
newborn infants, 1-2% develops serious neonatal infection.
A number of factors are known to increase the risk of neonatal early-onset infection in 
the presence of GBS in the birth canal: preterm delivery (before 37 weeks of gestation), 
prolonged rupture of the membranes (more than 18-24 hours), intrapartum fever (>38.0 
°C), extensive maternal GBS colonisation (which may present as GBS urinary tract 
infection or GBS bacteriuria during pregnancy), and a history of a previous child with 
invasive neonatal GBS diseas. 9,10 About 90% of all cases of neonatal GBS infections are of 
the early-onset type, occurring in the fi rst seven days of life. Early-onset GBS-infections 
usually originate from vertical transmission from the birth canal. Most infants with early-
onset GBS disease show symptoms at birth and more than 90% are diagnosed on the fi rst 
day of life. Mostly symptoms of sepsis and/or pneumonia occur and in 15% of the cases a 
meningitis. 4,5 Late-onset neonatal infections, occurring between 8 and 90 days after birth, 
are caused by vertical as well as horizontal transmission. The incidence of meningitis 
is approximately 30% of the cases. 11 Late-onset GBS infections usually are caused by 
serotype III. 
Epidemiology
In Europe there are little published data on national incidence rates of early-onset 
GBS-disease. The reported incidence of proven neonatal early-onset GBS sepsis in some 
European countries varies from 0.5 to 1.15 per 1000 live born infants. 12-15 We studied the 
nationwide incidence of early-onset GBS disease (sepsis and probable sepsis) during a 
2-year period (1997-1998) in the Netherlands and found an overall incidence of about 1.9 
per 1000 live born infants. The incidence of proven neonatal early-onset GBS-sepsis alone 
was 0.6 per 1000 live births. In the USA the case fatality rate used to be over 50% in the 
1970s, but currently it has decreased to below 10%.16 In the Netherlands we found a case 
fatality rate for early-onset GBS-disease of 5%.4 
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Prevention Strategies
Diagnostic procedures
Screening for maternal GBS-carriership is best done by taking material from the entrance 
to the vagina followed by a smear from the rectum with the same swab. Both sites 
are more often colonised than the cervix.17 In addition, vertical transmission is highest 
with colonisation of the entrance to the vagina. Culture in a selective broth is the 
gold standard. Non-selective media decrease detection by more than 50%.18 A major 
disadvantage of the culture method is the delay of 24-48 h before the result is available. 
For that reason more rapid diagnostic methods were developed. Rapid GBS tests (results 
known within 0.5-2 h) are usually based on direct identifi cation of the group-specifi c 
polysaccharide antigen by latex-agglutination or enzyme-immuno-assay. Specifi city is high 
(92-100%), but the sensitivity seems to be too low (15-60%) to promote its general use as 
a diagnostic test. 19 Recently a new rapid test was developed for detection of GBS-antigen 
in vaginal specimens using a new optical immunoassay technique. The sensitivity of this 
rapid test is claimed to be higher (70%) and the result is known in 30 minutes. 20 The 
most recent method uses a polymerase-chain-reaction (PCR) assay for the rapid detection 
of GBS colonisation. The sensitivity seems to be higher (97%) than that of the latex-
agglutination and enzyme-immuno-assay tests. 21 
Chemoprophylaxis
Intravenous antibiotic prophylaxis of the mother during delivery is regarded as the most 
effective method to reduce the number of neonatal infections. 22,23 Intravenous prophylaxis 
with 5 million IU penicillin G or 2 g amoxicillin or ampicillin should ideally be started 4 
hours before birth, followed by respectively 2.5 million IU penicillin or 1 g amoxicillin 
or ampicillin each 4 hours until delivery. Chemoprophylaxis is regarded to be adequate 
if at least two doses are administered. Penicillin is the fi rst choice because of the narrow 
spectrum and less risk of selection of resistant bacteria. 24 In case of penicillin allergy, 
clindamycin (900 mg intravenously every 8 h until delivery) or erythromycin (500 mg 
intravenously each 6 h until delivery) is given. Antibiotic treatment of GBS carriers during 
pregnancy is inadequate as prophylaxis, as vaginal re-colonization from the gut often 
occurs. Prolonged prophylactic treatment can result in resistance of other micro-organisms 
and disturbance of the intestinal and vaginal fl ora. 
Vaginal chlorhexidine disinfection
Vaginal disinfection with chlorhexidine during labour was suggested as a simple, cheap 
and safe alternative to prevent vertical transmission and subsequent neonatal early-onset 
GBS disease. This method is without risk of bacterial resistance and with almost no risk of 
allergic complications. In a randomised study the application of vaginal disinfection with 
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chlorhexidine gel resulted in a limited reduction of vertical transmission of GBS (about 
17%).25 However, studies with chlorhexidine showed confl icting results and a defi nite 
conclusion on the effect of this treatment on the incidence of neonatal sepsis cannot be 
drawn. 26,27 In the presence of risk factors for early-onset neonatal infection chlorhexidine 
is certainly not an alternative for intravenous antibiotic prophylaxis during labour.
Immunization
In the future, immuno-prophylaxis will become important. Immunization of women 
during or before pregnancy protects infants from perinatally acquired infection by 
transplacental transfer of protective IgG antibodies. 28 Since transport across the 
placenta is limited before 34 weeks gestation, preterm babies are less well protected. A 
monovalent protein-conjugate vaccine containing capsular polysaccharide antigens of 
serotype III, Ia, Ib and II has been produced, with encouraging results. 29-31 However, 
there are shifts in the GBS serotypes causing disease and an effective vaccine given to the 
mother that protects against all serotypes of GBS is not yet available.
Prevention strategy of early-onset GBS disease in the USA.
In the USA guidelines for prevention of early-onset GBS disease have been approved by 
the American Academy of Paediatrics (AAP), the American College of Obstetricians and 
Gynaecologists (ACOG) and the Center for Disease Control and Prevention (CDC) since 
1996. 1,2 In these guidelines either one of two strategies for prevention are recommended. 
Firstly, intrapartum chemoprophylaxis should be offered to all women identifi ed as GBS 
carriers at 35 - 37 weeks and, when the screening culture is not performed or the result 
is unknown, to all women with the following risk-factors at the time of labour: premature 
onset of labour (<37 weeks), prolonged rupture of membranes (>18 h), intrapartum fever 
(> 38°C), GBS bacteriuria during the current pregnancy and a previous delivery of an 
infant with invasive GBS disease. 
Secondly, intrapartum chemoprophylaxis should be offered to all women with one 
or more of the following risk-factors at the time of labour: premature onset of labour 
(<37 weeks), prolonged rupture of membranes (>18 h), intrapartum fever (> 38°C), 
GBS bacteriuria during the current pregnancy and a previous delivery of an infant with 
invasive GBS disease.
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Prevention strategy of early-onset GBS disease in the Netherlands
In the Netherlands the Dutch Society of Paediatrics and the Dutch Society of Obstetrics 
and Gynaecology approved the guidelines for prevention of early-onset GBS disease in 
1998. These guidelines were based on the risk factor-based approach as is recommended 
in the USA in 1996 as one of the two best strategies. 1,2 
Intrapartum chemoprophylaxis is recommended following a previous delivery of an infant 
with invasive GBS disease, or heavy maternal GBS colonization (which may present as 
GBS urinary tract infection or GBS bacteriuria during the current pregnancy). In the case 
of intrapartum maternal fever (> 38°C) broad-spectrum antibiotics are started. In the case 
of onset of labour before 37 weeks of gestation and prolonged rupture of membranes 
(>18-24 hours before delivery), screening for GBS carriage is performed fi rst, followed 
by chemo-prophylaxis when the culture is positive. When the delivery occurs before the 
result of the culture is available, the obstetrician should decide about chemoprophylaxis, 
based on the severity of the risk factor(s) (fi g.1).
Post delivery management 
Prophylactic administration of antibiotics to the mother is discontinued after delivery, 
unless symptoms of maternal infection persist. In that case prophylaxis is changed 
to therapy with a change of antibiotic strategy, if needed. A differentiated sequential 
management of newborn infants of GBS carriers who had an indication for antibiotic 
prophylaxis seems to be justifi ed. First of all, it should be established whether adequate 
antibiotic prophylaxis was given during delivery. Prophylaxis can be regarded as 
adequate if the antibiotic drug was given intravenously in the right dosage and at least 4 
h before birth (meaning two dosages). After adequate prophylaxis, observation during 48 
h, of which at least 24 h must be in hospital, is suffi cient. If no or inadequate prophylaxis 
was given and gestation was more than 35 weeks, the same strategy is followed. If no 
or inadequate prophylaxis was given and gestation was less than 35 weeks, a culture is 
taken from blood, cerebrospinal fl uid, ear and nasopharynx and treatment for sepsis is 
started. If the cultures of blood and of cerebrospinal fl uid are negative and no clinical 
signs of infection are present, treatment can be stopped earlier. If clinical signs of 
infection exist, an extensive diagnostic approach for infection is indicated and the infant 
is treated as in sepsis, independently of the prophylaxis and the gestational age (fi g.1).
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Pregnancy
Risk factor neonatal early onset GBS sepsis
• Preterm
• Prolonged rupture of
membranes
• GBS bacteriuria during
current pregnancy
• Previous child with GBS
disease
• Maternal fever during
delivery
N Y Y Y
GBS diagnostics Lab for infection without delay
No GBS carrier GBS carrier *
No antibiotic
prophylaxis during
delivery
Antibiotic
prophylaxis during
delivery
Antibiotics,
without delay
Adequate Not Adequate
Symptoms
of infection
< 35 wks > 35 wksNo special
measures
• Culture of ear and
nasopharynx
• 48 hrs observation
• Culture of ear and
nasopharynx
• 48 hrs observation
•Culture of blood  ,CSF, ear
and nasopharynx
•treat as neonatal sepsis
*  In case of delivery before receiving the results of cultures the obstetrician should decide about antibiotic prophylaxis, based on the severity of 
the risk factor(s)
Figure 1. Prevention strategy of early onset GBS disease in the Netherlands
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Discussion
In the USA there was no consensus about the best strategy for prevention of early-onset 
GBS infection. Rouse et al. 32 calculated that the screening-based strategy results in 
intrapartum chemoprophylaxis for 26.7% of all pregnant women and would prevent 
nearly 90% of cases with neonatal GBS-disease. With the risk factor only-based strategy 
18% of all pregnant women receive intrapartum chemoprophylaxis and this strategy 
would prevent 69% cases of neonatal GBS disease. Cost-effectiveness of these two 
strategies is similar. Recently the CDC published a report with revised guidelines for 
prevention of perinatal GBS disease in the USA. 33 Many of the recommendations are 
the same as those in 1996. 1 The most important change is that only one strategy is 
recommended, the screening-based strategy, universal screening for vaginal and rectal 
colonisation of all pregnant women at 35-37 weeks gestation. This recommendation 
is based on data found in a recent study of comparison of the two strategies and they 
concluded that the screening-based strategy was >50% more effective than the risk factor 
based strategy. 34 Management strategy depends on local factors like the percentage 
of GBS carriers and the percentage of pregnant women with perinatal risk factors 
within the population, the organisation of perinatal care and the local availability of 
laboratory facilities. The choice for a preventive strategy should be based on rationality, 
cost-effectiveness and the current knowledge and possibilities. The Dutch guidelines 
for prevention of early-onset GBS disease were posted before the defi nitive results 
of the study of the nationwide incidence in the Netherlands were known, and it was 
thought that the total incidence of proven and probable sepsis was relatively low (0.9 
per 1000 live births), compared with the incidence in the USA before the introduction 
of guidelines. The Dutch organisation of obstetrical care has approximately 30 % home 
deliveries. Midwives and general practitioners care for these pregnancies. Women with 
one of the fi ve risk factors, as described in the guidelines, will always be referred to 
a hospital. For these reasons a strategy based on recognition of these fi ve risk factors 
was proposed. To further reduce the number of women that would receive antibiotic 
prophylaxis during delivery, it was recommended that in case of premature onset of 
labour (<37 weeks) and/or prolonged rupture of membranes (>18-24 h), screening for 
GBS carriership is performed fi rst, followed by chemoprophylaxis when the culture is 
positive. In case the delivery occurs before the result is available, the obstetrician should 
decide about antibiotic prophylaxis, based on the severity of the risk factor (fi g.1). 
Both the screening and risk-based prevention strategy leads to the use of prophylactic 
antibiotics in a substantial number of pregnant women and the adverse effects of these 
strategies must be considered. One of the adverse effects is the development of antibiotic 
resistance. Resistance to penicillin in GBS has been described but is rare and not a 
clinical problem. Resistance to erythromycin and clindamycin has been reported in 7.4% 
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and 3.4% of invasive GBS isolates respectively. 35 This has some clinical relevance as 
these agents are recommended for intrapartum prophylaxis in women with a history of 
penicillin allergy. For this reason in the last report of the CDC the recommendation is 
changed. In case of penicillin allergy when the patient is not at high risk for anaphylaxis, 
cefazolin is given and if the patient is at high risk for anaphylaxis, vancomycin is given. 
33 The use of ampicillin rather than penicillin for intrapartum GBS prophylaxis has been 
reported to be associated with an increase in the incidence of neonatal sepsis caused 
by ampicillin-resistant Gram-negative micro-organisms. Another important adverse effect 
is the increasing incidence of potential severe adverse reactions including anaphylaxis 
to penicillin. 32,36 Other disadvantages of intrapartum chemoprophylaxis are the medical 
interference in normal labour and in the neonatal period as well as increased demand for 
prenatal counselling and increased maternal anxiety. 
Conclusions
The Dutch ‘risk-based’ strategy tries to reduce the number of pregnant women that 
will receive prophylactic antibiotics. The disadvantage of this strategy is that it must be 
accepted that 30-40% of neonatal early-onset GBS-infections may occur in the absence 
of risk factors. 4 Therefore we decided to study the compliance of the Dutch guidelines 
for prevention of early-onset GBS disease and the effect on the incidence of early-onset 
GBS-infection in the Netherlands in the fi rst 3 years after introduction (1999, 2000 and 
2001). Depending on the results of this study, it may be necessary to change the Dutch 
guidelines in the future. 
Acknowledgements
Zorg Onderzoek Nederland (proj. nr. 2200004) fi nanced this study
Strategy to prevent neonatal early-onset GBS disease 25
References
 1. CDC. Prevention of perinatal group B streptococcal disease: a public health perspective. 
MMWR 1996; 45:1-24.
 2. American Academy of Pediatrics. Revised Guidelines for Prevention of Early-onset Group B 
Streptococcal (GBS) infection. Pediatrics 1997; 99:489-96.
 3. Schrag S, Zywicki S, Farley MM, Reingold AL, Harrison LH, Lefkowitz LB et al. Group B 
Streptococcal disease in the era of intrapartum antibiotic prophylaxis. N Engl J Med 2000; 
342:15-20.
 4. Trijbels-Smeulders M, Gerards LJ, Pasker-de Jong PCM, van Lingen RA, Adriaanse AH, de 
Jonge GA et al. Epidemiology of neonatal group B streptococcal disease in the Netherlands 
1997-1998. Paediatr Perinat Epidemiol 2002;16:334-41.
 5. Schuchat A, Wenger JD. Epidemiology of Group B Streptococcal Disease. Epidemiol Rev 
1994;16:374-402.
 6. Boyer KM, Gadzala CA, Kelly PD, Burd LI, Gotoff SP. Selective intrapartum chemoprophylaxis 
of neonatal Group B Streptococcal early-onset disease. Predictive value of prenatal cultures. J 
Infect Dis 1983;148:802-9.
 7. Hoogkamp-Korstanje JAA, Gerards LJ, Cats BP. Maternal carriage and neonatal acquisition of 
Group B Streptococci. J Infect Dis 1982;145:800-3. 
 8. Adriaanse AH. Prevention of neonatal septicaemia due to Group B Streptococci. Ballieres Clin 
Obstet Gynaecol 1995;9:545-52.
 9. Bramer S, van Wijk F, Mol B, Adriaanse AH. Risk indicators for neonatal early-onset GBS 
related disease. A case-control study. J.Perinat Med 1997;25:469-75.
 10. Schuchat A, Deaver-Robinson K, Plikaytis B. Multistate case-control study of maternal risk 
factors for neonatal Group B Streptococcal disease. Pediatr Infect Dis J 1994;13:623-9.
 11. Zangwill KM, Schuchat A, Wenger JD. Group B streptococcal disease in the United States 
1990: report from a multistate active surveillance system. MMWR CDC Surveill Summ 
1992;41:25-32.
 12. Mayon-White RT The incidence of GBS disease in neonates in different countries. Antibiot 
Chemother1985;35:17-27.
 13. Aavitsland P, Hoiby E, Lystad A. Systemic group B streptococcal disease in neonates and 
young infants in Norway 1985-94. Acta Paediatr 1996;85:104-5.
 14. Moses L, Heath P, Wilkinson A, Jeffery H, Isaacs D. Early onset group B streptococcal 
neonatal infection in Oxford 1985-96. Arch Dis Child Fetal Neonatal Ed 1998;79:F148-9.
 15. Bignardi G. Surveillance of neonatal group B streptococcal infection in Sunderland. Commun 
Dis Public Health 1999;2:64-5.
 16. Schuchat A. Neonatal group B streptococcal disease. Screening and prevention. N Engl J Med 
2000;343:209-10.
 17. Dillon HC, Gray E, Pass MA, Gray BM. Anorectal and vaginal carriage of group B streptococci 
during pregnancy. J Infect Dis 1982;145:794-9.
 18. Baker CJ, Goroff DK, Alpert S. Vaginal colonisation with group B streptococcus: a study of 
college women. J Infect Dis 1977;135:392-7.
 19. Adriaanse AH, Muytjens HL, Kollée LAA, Nijhuis JG, Eskes TKAB. Sensitivity of intrapartum 
group B streptococcal screening and in vitro comparison of four rapid antigen tests. Eur J 
Obstet Gynecol Reprod Biol 1994;56:21-6.
 20. Park CH, Ruprai D, Vandel NM, Hixon DL, Mecklenburg FE. Rapid detection of Group B 
Streptococcal antigen from vaginal specimens using a new Optical Immunoassay technique. 
Diagn Microbiol Infect Dis 1996;24:125-8.
 21. Bergeron MG, Ke D, Menard C, Picard FJ, Gagnon M, Bernier M, et al. Rapid detection of 
group B streptococci in pregnant women at delivery. N Engl J Med 2000;343:175-9. 
 22. Boyer KM, Gotoff SP. Prevention of early-onset neonatal group B streptococcal disease with 
selective intrapartum chemoprophylaxis. N Engl J Med 1986;314:1665-9.
 23. Allen UD, Navas L, King SM. Effectiveness of intrapartum penicillin prophylaxis in preventing 
early-onset group B streptococcal infection: results of a meta-analysis. Can Med Assoc J 
1993;149:1659-65.
 24. Amstey MS, Gibbs RS. Is Penicillin G a better choice than ampicillin for prophylaxis of 
neonatal group B streptococcal infections? Obst Gynecol 1994;84:1058-9. 
 25. Adriaanse AH, Kollée LAA, Muytjens HL, Nijhuis JG, de Haan AFJ, Eskes TKAB. Randomised 
study of vaginal chlorhexidine disinfection during labour to prevent vertical transmission of 
group B streptococci. Eur J Obstet Gynecol Reprod Biol 1995;61:135-41.
 26. Burman LG, Christensen P, Christensen K. Prevention of excess neonatal morbidity associated 
with group B streptococci by vaginal chlorhexidine disinfection during labour. The Swedish 
Chlorhexidine Study Group. Lancet 1992;340:65-9.
 27. Taha ET, Biggar RJ, Broadhead RL. Effect of cleansing the birth canal with antiseptic solution 
on maternal and newborn morbidity and mortality in Malawi: clinical trial. BMJ 1997;315:216-
9. 
 28. Schuchat A, Wenger JD. Epidemiology of group B streptococcal disease: risk factors, 
prevention strategies and vaccine development. Epidemiol Rev 1994;16:374-402.
 29. Kasper DL, Paoletti LC, Wessels MR. Immune response to type III group B streptococcal 
polysaccharide-tetanus toxoid conjugate vaccine. J Clin Invest 1996;98:2308-14. 
 30. Baker CJ, Paoletti LC, Wessels MR. Safety and immunogenicity of capsular polysaccharide-
tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib. J Infect Dis 
1999;179:142-50.
 31. Baker CJ, Paoletti LC, Rench MA. Use of capsular polysaccharide-tetanus toxoid conjugate 
vaccine for type II group B streptococcus in healthy women. J Infect Dis 2000;182:1129-38.
 32. Rouse DJ, Goldenberg RL, Cliver SP. Strategies for the prevention of early-onset neonatal 
group B streptococcal sepsis : a decision analysis. Obstet Gynecol 1994;83:483-94.
 33. CDC. Prevention of perinatal group B streptococcal disease: revised guidelines from CDC 
MMWR 2002;51:1-24. 
 34. Schrag SJ, Zell ER, Lynfi eld R, Roome A, Arnold KE, Craig AS et al. A population-based 
comparison of strategies to prevent early-onset group B streptococcal disease in neonates. N 
Engl J Med 2002;347:233-9.
 35. Fernandez M, Hickman ME, Baker CJ. Antimicrobiol susceptibilities of group B streptococci 
isolated between 1992 and 1996 from patients with bacteremia or meningitis. Antimicrob 
Agents Chemother 1998;42:1517-9.
 36. Mohle-Boetani JC, Schuchat A, Plikaytis BD. Comparison of prevention strategies for neonatal 
group B streptococcal infection: a population-based economic analysis. JAMA 1993;270:1442-
8. 
C3Neonatal group B streptococcal 
infection: incidence and strategies 
for prevention in Europe
Monique A.J.M. Trijbels-Smeulders, Louis A.A Kollée, Albert H. 
Adriaanse, Jan L.L. Kimpen and Leo J. Gerards.
The Pediatric Infectious Disease Journal 2004;23:172-3
28 Chapter 3
Abstract 
We sent a questionnaire to all members of the European Society for Paediatric Infectious 
Diseases and to all delegates of the European Association of Perinatal Medicine to 
determine existing policies for prevention of neonatal group B streptococcal (GBS) 
infection in Europe. The incidence of GBS colonization in pregnant women and of 
neonatal GBS infection varies. Policies for prevention of GBS infection are not well 
developed.
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Introduction
In the industrialized world Group B Streptococci (GBS) are the leading cause of severe 
bacterial infections during the fi rst three months of life. In 1996 the CDC recommended 
two different strategies for prevention of perinatal group B streptococcal disease, the 
screening-based strategy and the risk-based strategy. 1 After implementation of the 
guidelines in the US, the incidence of early onset GBS disease dropped signifi cantly 
from 1.7 per 1000 live births in 1993 to 0.6 per 1000 live births in 1998. 2 In 2002 the 
CDC recommended the screening-based strategy as the only strategy for prevention of 
perinatal GBS disease. 3 This recommendation was based on a comparative study in 
which the screening-based strategy was > 50% more effective than the risk factor based 
strategy. 4 
From Europe only limited data about maternal GBS colonization and incidence of 
neonatal GBS disease are available. The goal of our study was to gain insight into the 
epidemiology of neonatal GBS disease and existing policies for prevention in Europe.
Materials and methods
In December 1999 a questionnaire was sent to all members (327) of the European 
Society for Paediatric Infectious Diseases (ESPID) and to all 50 national delegates of 
the European Association of Perinatal Medicine (EAPM) in 33 European countries. 
Questions were asked on the availability of data with respect to the incidence of maternal 
GBS-colonization and of neonatal GBS-infection (0 to 3 months) in their country and 
the presence of nationwide or hospital-based guidelines for prevention of early-onset 
GBS-infection. 
Respondents from countries without offi cial nationwide guidelines for prevention of 
GBS infection were asked to answer some questions regarding their personal policy 
for prevention of GBS disease. To evaluate the obstetrical policy, it was asked whether 
the respondent would give antibiotics during labor to a pregnant woman (1) with signs 
of infection (2) in case of preterm delivery and (3) if membranes were ruptured for > 
18 and 24 h, respectively. To evaluate the policy with respect to the infant of a known 
GBS-colonized mother, the respondents were asked whether they would administer 
antibiotics to such a newborn infant in the absence of signs of infection if the mother was 
adequately treated with antibiotics before delivery and if the infant was born before or 
after 37 weeks gestation respectively. The same questions were asked in case the mother 
was not or inadequately treated with antibiotics. 
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Results
The total number of questionnaires sent was 377 and 55 respondents returned the 
questionnaire, the overall response rate was only 15%. Twenty-nine of the respondents 
were ESPID-members (29 of 327 = 9%) from 18 European countries and 26 were EAPM 
members (26 of 50 = 52%) from 21 European countries. Of the 33 European countries 
involved, 29 were represented by at least one respondent. The four countries that did not 
respond were Bulgaria, Ireland, Russia and Yugoslavia. 
The reported incidence of GBS colonization among pregnant women ranged from 1.5 to 
22% in Eastern Europe, from 7 to 30% in Western Europe, from 10 to 25% in Scandinavia 
and from 2.3 to 18.5% in the Southern part of Europe (table 1). No data about GBS 
colonization among pregnant women became available from Austria, Estonia, Latvia, 
Poland, Portugal, Romania and Scotland.
Table 1 GBS colonization during pregnancy and incidence of neonatal GBS infection in diﬀ erent European countries 
GBS colonization
(% of pregnant women)
incidence of GBS- infection
(per 1000 live births)
Eastern Europe
 Croatia
 Czech Republic
 Estonia
 Hungary
 Latvia
 Lithuania
 Poland
 Romania
 Slovak Republic
 Slovenia
 Ukraine
Western Europe
 Austria
 Belgium
 France
 Germany
 Scotland
 Switzerland
 The Netherlands
 United Kingdom
Scandinavia
 Denmark
 Finland
 Iceland
 Norway
 Sweden
Southern Europe
 Greece
 Italy
 Portugal
 Spain
Turkey
1.5
8.5-22
--
5 – 20
--
20
--
--
15 – 20
10
18.7
--
20
20 5 **
7-15
--
10 – 15
5 – 20 6
20 – 30 8
10 10
15
25
15 – 20
25
7 – 13
18.5
--
12 – 14.7
2.3-13.6
-- *
0.2-1.1
--
1 – 2
--
--
--
--
1 – 4
1.8 
--
2
2
0.3-0.4
--
--
--
1.9 7
0.5-2 9
--
0.76
0.9 
1 – 2 11
1
--
0.9
--
0.57 – 2 12
--
* no data available
** if data were published, the reference is given
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The incidence of neonatal GBS infection was reported to be 0.2 to 4 per 1000 live births 
in Eastern Europe, 0.3 to 2 per 1000 live births in Western Europe, 0.76 to 2 per 1000 
live births in Scandinavia and 0.57 to 2 per 1000 live births in Southern Europe (table 
1). No data about the incidence of neonatal GBS infection were available from Croatia, 
Denmark, Estonia, Germany, Greece, Latvia, Lithuania, Poland, Portugal, Romania, 
Scotland, Switzerland, Turkey and Ukraine. Nationwide guidelines to prevent neonatal 
GBS infection were available in only 4 of 29 (14%) European countries: Denmark, the 
Netherlands, Norway and Spain. Spain has a screening-based guideline and Denmark, 
Norway and the Netherlands have a risk factor based guideline. In Belgium, Slovak 
Republic and United Kingdom, the establishment of a nationwide protocol was reported 
to be in progress. 
Respondents from 10 countries reported that in their hospital a local protocol for 
prevention of neonatal GBS disease exists. These countries are: Czech Republic, Finland, 
France, Germany, Hungary, Iceland, Portugal, Slovenia, Sweden and Switzerland. 
Respondents of the 11 remaining countries reported the absence of both a nationwide 
and a local protocol.
Almost all respondents (96%) from the 25 countries without nationwide guidelines to 
prevent neonatal GBS infection would give antibiotics to women with signs of infection 
during labor. 
In case of preterm birth (< 37 weeks), ruptured membranes for > 18 or 24 h, respectively, 
53, 54 and 65% of the respondents would give antibiotics during labor. When GBS-
positive mothers were adequately treated during labor, administration of antibiotics to 
infants without signs of infection would be decided for by 48% of the respondents if 
preterm and 19% if term. When mothers were not or inadequately treated during labor, 
61% of the infants born before 37 weeks gestation and 35% of term infants would be 
treated with antibiotics after birth.
Discussion
The aim of the study was to establish the incidence of GBS-colonization in pregnant 
women and the incidence of neonatal GBS-infection and to determine policies for 
prevention of neonatal GBS-infection in Europe. The response rate of 15 % was low, but 
29 of the 33 European countries involved were represented by at least one respondent. 
Therefore we believe that we have received a reasonable impression of these incidences.
The data collected show that in most European countries the incidence of GBS 
colonization among pregnant women varies between 10 and 20 % and the incidence 
of neonatal GBS- infection ranges from 0.5 to 2 per 1000 live births. The differences 
found may be partly explained by the use of different data collection sources (regional, 
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national), differences in defi nition of GBS sepsis used (probable and/or proven cases) 
and differences in the culture methods used.
Nationwide guidelines for prevention have been issued in only a few European countries 
thus far. About one-half of the respondents reported the existence of local hospital-based 
protocols in their institution, but the prevention practices vary among doctors and 
institutions. The policy of giving antibiotics to pregnant women with signs of infection 
during delivery is widely accepted. However, only about one-half of the respondents 
would give antibiotics in case of expected preterm delivery and after prolonged rupture 
of the membranes.
When pregnant women are identifi ed as being colonized with GBS, most respondents 
would not give antibiotics to prevent early-onset GBS-infection to the infant in case of 
term delivery and absence of neonatal signs of infection, whether or not intrapartum 
antibiotic prophylaxis was given. However, about one-half of the respondents would 
do so after preterm delivery, especially if no or inadequate intrapartum prophylaxis was 
given. 
Our study shows that only four European countries have a nationwide guideline for 
prevention of early-onset GBS infection. Because of the lack of epidemiological data and 
uniform early-onset GBS infection prevention methods, a surveillance study in European 
countries would be needed for determination of the most appropriate prevention policy. 
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Summary
Group B streptococcal (GBS) infection still is an important cause of morbidity and 
mortality in newborn infants. In the Netherlands, there are no published data on the 
incidence of neonatal GBS infection. We collected data of all infants with GBS disease 
during the fi rst 3 months of life, as reported to the Dutch Paediatric Surveillance Unit 
(DPSU) during a period of 2 years (1997-98). Neonates with early-onset GBS disease 
(both sepsis and probable sepsis) were included for further analysis. The level of 
completeness of the DPSU data was determined by capture-recapture techniques.
The incidence of early-onset GBS disease in the Netherlands in 1997-98, as calculated 
from the DPSU data, was 0.9 per 1000 live births. After correction for underreporting 
the incidence was estimated to be 1.9 per 1000 live births. The case fatality rate of 
early-onset GBS disease was only 5%. Despite the decrease of the mortality rate during 
the last decades, it remains a serious condition with potential irreversible brain damage. 
Therefore, formal guidelines for the prevention of neonatal early-onset GBS disease in 
the Netherlands were introduced in 1999. The data collected in this study may serve as 
baseline data for evaluation of the effect of these guidelines.
Neonatal GBS disease in 1997-1998 37
Introduction 
Group B streptococcal (GBS) infection has been recognised as an important cause of 
morbidity and mortality in newborn infants since the 1970s. During the last 30 years, 
the case fatality rate of neonatal early-onset GBS disease decreased from about 50% to 
< 10%.1 There is no evidence in the literature that the incidence in Europe decreased 
signifi cantly in this period. The incidence of culture-confi rmed cases of neonatal early-
onset GBS disease in some European countries is reported to vary from 0.5 to 1.15 per 
1000 live born infants.2-4 In the USA, the incidence before the introduction of formal 
guidelines for prevention in the early 1990s was higher and varied from 1.1 to 3.7 per 
1000 live born infants.1 After the introduction of guidelines, approved by the American 
Academy of Pediatrics, the American College of Obstetricians and Gynecologists and the 
Centers for Disease Control and Prevention, the incidence of culture-confi rmed cases of 
systemic neonatal early-onset GBS disease in selected areas of the USA decreased from 
1.7 per 1000 live births in 1993 to 0.6 per 1000 live births in 1998.5,6
No published data are available on the incidence of neonatal GBS infection in the 
Netherlands. We studied the nation-wide incidence during a period of two years (1997-98) 
and collected data from infants with GBS disease diagnosed before the age of 90 days. In 
the Netherlands, formal guidelines for the prevention of neonatal early-onset GBS-disease 
did not exist during this time period. These were issued in 1999, and the data collected in 
this study may serve as a baseline for evaluation of the effect of these guidelines. 
Methods
To determine the incidence of neonatal GBS disease during the 2-year period 1997-98, 
we co-operated with the Dutch Paediatric Surveillance Unit (DPSU). This unit co-
ordinates an ‘active’ case reporting structure; it was set up in October 1992, to facilitate 
the investigation of infrequent illnesses in children in the Netherlands. Its methodology 
involves the monthly mailing of a card that contains a variable menu of 10 reportable 
conditions to all paediatricians who are involved in clinical hospital care. In 1997 and 
1998, respondents were requested to report the number of cases of GBS disease that 
occurred during the fi rst 3 months of life and had been diagnosed in the preceding 
month, by returning the card. Every month, the DPSU forwarded the names of the 
paediatricians who reported cases of GBS disease to one of the authors (M.T.S.), who 
then sent them a questionnaire. The questionnaire (an English version of which is 
available from the fi rst author) contained items concerning clinical, microbiological and 
biochemical data of both mother and child. This procedure resembles that of the British 
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Paediatric Surveillance Unit (BPSU) which also included neonatal GBS disease in its 
reporting card from February 2000.
We decided to include neonates with GBS sepsis as well as neonates with probable GBS 
sepsis. GBS disease occurring in the fi rst 7 days or between 8 and 90 days after birth was 
regarded as “early-onset” and “late-onset” respectively.
The diagnosis of GBS sepsis was based on the simultaneous presence of both clinical 
features of septicaemia (physical signs such as poor perfusion or shock, apnoea, 
respiratory distress and abnormal results of laboratory investigations such as leucocytosis 
or leucopenia, granulocytopenia, shift to the left, thrombocytopenia, elevated CRP) and a 
positive GBS culture of blood and/or cerebrospinal fl uid (CSF). The diagnosis of probable 
GBS sepsis was based on the presence of the same clinical features (including both 
physical signs and abnormal results of laboratory investigations), and the isolation of GBS 
from various sites, but in the absence of positive blood and/or CSF cultures.7,8 
Four well-known obstetric risk-factors of early-onset GBS disease were documented: 
delivery before 37 weeks of gestation, >18 h duration of ruptured membranes, 
intrapartum fever ( >38.0 0 C) and previous delivery of a child with neonatal GBS 
disease.9,10
Because reporting to the DPSU is voluntary, and variation in completeness of the 
data reported has been documented, we had to correct the results of the study for 
under-reporting. In order to do so, we used capture-recapture techniques to estimate 
the number of cases missed by the DPSU. Capture-recapture techniques use the total 
number of cases reported to each of two independent sources. The corrected total 
number of cases can be calculated from the numbers reported by both sources and the 
overlap between them.11 For this method to be valid, the second source needs to be 
independent of the main source (reporting in the DSPU). The second source we used 
was the response after an advertisement in a national parents’ magazine in which we 
asked parents to report to one of us (GdJ), if they had a child with GBS disease before 
the age of 90 days in 1997 or 1998. Following the parental report and after their consent, 
relevant information was requested from the paediatrician involved. The case was then 
classifi ed as GBS sepsis, probable GBS sepsis or discarded, similar to the procedure for 
the cases reported to the DPSU. Finally, we checked whether individual cases reported 
by parents had also been reported to the DPSU by paediatricians. We also estimated 
the level of completeness of reporting of GBS meningitis to the DSPU to see whether 
reporting to the DPSU may have been selective for more severe cases. In the Netherlands, 
a signifi cant proportion of CSF cultures from patients with proven meningitis are sent to 
the microbiology laboratory of the Academic Medical Centre in Amsterdam as the national 
reference laboratory for bacterial meningitis. The data from this laboratory were used as a 
second source for the cases of GBS-meningitis.
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Follow-up data for the infants with GBS disease were not collected. This study was 
approved by the medical ethics committee of the University Medical Centre, Nijmegen.
Results
Study population 
Over the period 1 January 1997 to 31 December 1998, 642 cases of GBS disease were 
reported to the DPSU (fi gure 1). Of these, 66 reports were excluded from the study 
because they were double reports and 198 because they were incorrect and did not 
meet the inclusion criteria. Of the latter group, 126 reports were cases in which only 
GBS colonisation, without clinical features, were present. The remaining 378 cases were 
included in the study (fi gure 1). 
The diagnosis of early-onset GBS sepsis was made in 157 cases (42% of all cases 
included). In 18 of these (11% of early-onset GBS sepsis), meningitis was diagnosed 
as well. Early-onset probable GBS sepsis was diagnosed in 190 cases (50% of all cases 
included). The diagnosis of late-onset GBS sepsis was made in 27 cases (7% of all 
cases included). In 12 of the 27 cases with late-onset GBS sepsis (44%), meningitis was 
Study Population
642 cases
Reported to DPSU*
264 cases excluded
Early-onset GBS 
n = 347
Sepsis
n = 157
Probable
sepsis
n = 190
Meningitis 
n = 18/157 
(11%)
Sepsis
n = 27
Probable
sepsis
n = 4
Meningitis 
n = 12/27 
(44%)
378 cases included
Late-onset GBS 
n = 31
Figure 1.
Figure 1. Study population of cases of neonatal GBS disease reported to the Dutch Paediatric Surveillance Unit (DPSU) over the 
period 1997-98.
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diagnosed as well. Late-onset probable sepsis was diagnosed in four patients (1% of 
all cases included). Data for patients with early-onset GBS disease were analysed for 
epidemiological characteristics. The 31 cases of late-onset GBS disease were left out of 
the further analysis, because of the small number of patients involved. 
Incidence
We identifi ed 157 cases of early-onset GBS sepsis and 190 cases of early-onset probable 
GBS sepsis. In 1997-98, the total number of live births in the Netherlands was 391851. 
The incidence of early-onset GBS disease in this period, calculated from the DPSU 
reports, was therefore 0.9 per 1000 live births. 
In response to our request in a national magazine, parents reported 45 cases of early-
onset GBS disease (23 with early-onset GBS sepsis and 22 probable cases). Of these, 
25 were also reported to the DPSU (17 with early-onset GBS sepsis and eight probable 
cases). Therefore, the DPSU captured only 56% of the patients with early-onset GBS 
disease, 74% of the cases with early-onset GBS sepsis and 36% of the cases with early-
onset probable GBS sepsis (fi gure 2). After correction for underreporting, we estimate the 
overall incidence of early-onset GBS disease in the Netherlands in 1997-1998 as 1.9 [1.0, 
2.7] per 1000 live births. The incidence of early-onset GBS sepsis can be estimated as 0.6 
[0.4, 0.7] per 1000 live births and the incidence of early-onset GBS probable sepsis can be 
estimated as 1.3 [0.6, 2.1]. per 1000 live births. 
Early onset 
sepsis
national magazine
N=23
Early onset 
probable sepsis 
national magazine
N=22
Early onset sepsis
DPSU
N=157
Early onset
probable sepsis  
DPSU
N=190
Total:  56% captured by DPSU
17 8
Figure 2. Capture of cases of neonatal GBS disease both as reported by parents after an announcement in a national parents’ 
magazine and as reported to the DPSU by paediatricians
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A total of 29 neonates with GBS meningitis were reported to the reference microbiology 
laboratory of the Academic Medical Centre Amsterdam, 16 of whom were also reported to 
the DPSU. Therefore, the DPSU captured only 55% of the cases of GBS meningitis in the 
Netherlands in 1997-1998. 
Case-fatality
Twenty-one of the 347 patients with early-onset GBS disease died, fi ve of whom died 
from causes other than GBS disease. Eleven of 157 infants with early-onset GBS sepsis 
(7%) died. Of these, fi ve were preterm and fi ve showed signs of bronchopneumonia at 
post-mortem examination. Five of 190 (3%) infants with early-onset probable GBS sepsis 
died, four of whom were preterm. From the results of this study, it can be calculated that, 
in the Netherlands in 1997-98, the overall case-fatality rate of early-onset and late-onset 
GBS disease was 5% (16/347) and 7% (2/31) respectively. 
Epidemiological data of the infants
Data on gender, birthweight, twins, gestational age and case-fatality rate of the study 
population are listed in Table 1. Of all infants with early-onset GBS disease, 60% were 
boys. Infants with early-onset GBS sepsis had a 400 g lower mean birthweight and were 
more often preterm ( 37% vs. 26%) than infants with early-onset probable GBS sepsis. 
Almost all of the twins with early-onset GBS sepsis (17/19) and half of the twins with 
early-onset GBS probable sepsis (4/8) were preterm. As mentioned before 20 infants 
( 6 with early-onset GBS sepsis and 14 with early-onset probable sepsis), reported by 
parents, were not included in the DPSU and therefore not analysed. The data on gender 
and gestational age of these 20 infants did not differ from those included. 
Table 1. Study population: 347 newborn infants with early-onset GBS disease (1997-1998)
sepsis
(n = 157)
probable sepsis
(n = 190)
The Netherlands*
Male 90 (57%) 114 (60%) 51.1 % 
Birthweight Mean 2816 g 3202 g 3284 g
Range 725 – 4495 g 740 – 5050 g 700 – 5999
Twins 19 (12%) 8 (4%) 3.5% 
Gestation Mean 37 w + 6 d 38 w + 1 d
< 32 weeks 13 (8%) 14 (7%) 0.8 % 
≥ 32 - < 37 weeks 45 (29%) 35 (19%) 6.8 % 
≥ 37 weeks 99 (63%) 141 (74%) 92.4 % 
Case-fatality rate 11 (7%) 5 (3%) n.a.
* Best estimates from several sources ( f.e. CBS = Statistics Netherlands and Prismant (LVR) = Institute for health care management). 
n.a. = not available
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Maternal epidemiological data
Maternal data on age, parity, use of antibiotics during labour, induction of labour, place of 
delivery, mode of delivery and meconium staining of amniotic fl uid are listed in table 
2. The majority (93%) of infants with early-onset GBS disease were born in the hospital 
(321/347). In 90% of these, the indications for hospital delivery were one or more of the 
following seven factors: preterm delivery (33%), prolonged rupture of membranes (39%), 
intrapartum fever (18%), signs of intra-uterine infection (22%), meconium staining of 
amniotic fl uid (17%), induction of labour (27%), instrumental or operative delivery (38%). 
Cultures for maternal GBS carriership were taken during delivery in only 14% (48/347) of 
the cases and they were positive in 12% (42/347).
In the group of 20 infants with GBS-disease reported by parents, but not included in the 
analysis, parity, place of delivery and prolonged rupture of membranes (>18 h) did not 
differ from those included.
Table 2. Study population: mothers of 347 newborn infants with early-onset GBS disease (1997-1998).
Sepsis
(n = 157)
probable sepsis
(n = 190 )
The Netherlands*
Age 
Mean 29.9 yrs 29.9 yrs 30.5 yrs 
Range 17 – 38 yrs 17 – 41 yrs
First Parity 104 (66%) 120 (63%) 46.8 % 
Use of antibiotics 12 (8 %) 36 (19%) n.a.
Induction of labour 40 (25%) 48 (25%) 17 % 
Place of delivery
Home 14 (9%) 12 (6%) 30 %
Hospital 143 (91%) 178 ( 94%) 74.9 % 
Mode of delivery 
Spontaneous 110 (70%) 114 (60%) 76.6 % 
Instrumental 24 (15%) 28 (15%) 11.4 % 
Ceasarean section 23 (15%) 48 (25%) 10.5% 
Meconium stained 
Amniotic ﬂ uid
19 (12%) 37 (19%) 7.6 % 
* Best estimates from several sources (f.e. CBS = Statistics Netherlands and Prismant (LVR) = Institute for health care management) 
n.a. = not available 
First symptoms of early-onset GBS disease 
In 321 (93%) of the patients with early-onset GBS disease, the fi rst symptoms were 
observed within 24 h after birth and in 96% within 48 h after birth (fi g. 3). There was 
no difference in the presenting symptoms between patients with early-onset GBS sepsis 
and those with early-onset GBS probable sepsis. In most patients with early-onset 
GBS disease, grunting (in 38%) and signs of respiratory distress (in 30%) were the fi rst 
symptoms.
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Presence of risk factors
Table 3 shows the presence of obstetric risk factors in early-onset GBS sepsis and 
probable GBS sepsis. The overall occurrence of the individual risk factors in early-onset 
GBS disease was 31% for preterm delivery (n=107), 37% for prolonged rupture of the 
membranes (n = 130), 17% for intrapartum fever (n = 59) and 2% for previous delivery of 
a child with neonatal GBS disease (n=6).
The presence of preterm delivery and prolonged rupture of membranes was much more 
frequent in cases of early-onset GBS disease than in the general population of Dutch 
pregnant women. In 60% of all cases of early-onset GBS disease, one or more of these 
obstetric risk factors was present. One risk factor was present in 39 %, two risk-factors 
in16 % and three or more risk factors in 5%. In 40% of the cases, however, no known 
risk factors for GBS disease were present. Twenty-six term neonates with early-onset 
GBS disease were born at home. In 20 of these, no risk factor was present and, in six, 
prolonged rupture of the membranes had occurred. 
Table 3. Presence of risk-factors in 347 cases of early-onset GBS disease 
Risk-factors Sepsis
(n = 157)
probable Sepsis
(n = 190)
The Netherlands*
Preterm delivery
(<37 weeks)
60 (38%) 47 (25%) 7.6 % 
Prolonged rupture of membranes
(>18 hours)
56 (36%) 74 (39%) 10.8 % 
Intrapartum fever 
(> 38 °C)
26 (17%) 33 (17%) n.a.
Previous child with GBS-disease 1 (0,6%) 5 (3%) n.a.
* Best estimates from several source (f.e. CBS = Statistics Netherlands and Prismant (LVR) = Institute for health care management)
n.a. = not available
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Figure 3. Time of onset of symptoms of neonatal early-onset GBS disease
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Treatment of the mother during labour
Mothers of 12 neonates with early-onset GBS sepsis and mothers of 36 neonates with 
early-onset probable GBS sepsis were treated with antibiotics during labour (Table 2). 
Only one-third of these mothers were known to be colonised with GBS during labour 
(4/12 and 13/36 respectively) and almost all these mothers had one or more of the 
known risk factors for GBS (12/12 and 33/36 respectively). Of the mothers of the 11 
neonates with early-onset GBS sepsis and the mothers of the 31 neonates with early-onset 
probable GBS sepsis who were known to be colonised with GBS during labour, only 
about 40 % were treated with antibiotics during labour (4/11 and 13/31 respectively). 
Treatment of the neonates
Of the neonates with early-onset GBS disease, 237 (68%) were initially treated with 
amoxicillin and either gentamicin (133 ; 38%) or cephalosporin (39 ; 11%). In 15 neonates 
(4%) antibiotic treatment was started with penicillin and, in 49 neonates (14%) amoxicillin 
was replaced by penicillin after the blood culture was known to be positive for GBS. 
Mechanical ventilation was applied in 61 of 157 neonates (39%) with early-onset sepsis 
and in 48 of 190 neonates (25%) with early-onset probable GBS sepsis. Inotropic drugs 
and/or volume expansion were given in 79 neonates (50%) with early-onset GBS sepsis 
and in 59 neonates (31%) with early-onset probable GBS sepsis. Three patients, two with 
early-onset probable GBS sepsis and one with early-onset GBS sepsis were treated with 
extra corporal membrane oxygenation (ECMO).
Discussion
By using the facilities of the (DPSU), we found a nation-wide incidence for early-onset 
GBS disease (sepsis plus probable sepsis) of 0.9 per 1000 live births in The Netherlands in 
1997-98 and 0.4 per 1000 live births for (blood and/or CSF) culture proven cases of early-
onset GBS sepsis alone. However, the completeness of case reporting to the DPSU was 
only 56%, as we estimated by using additional sources of information on the occurrence 
of GBS disease. The capture-recapture technique requires two independent sources. We 
think that parents are a source independent from doctors. The results suggested that 
more severe cases (early-onset GBS-sepsis) were likely to be more completely reported. 
However, the completeness of reporting patients with both early-onset GBS-sepsis and 
meningitis (11%) to the DPSU was only 55%, and we imagine that there is underreporting 
of patients with meningitis because, in these septic patients, lumbar puncture is frequently 
omitted. The incidence of early-onset GBS disease was recalculated by the capture-
recapture technique and was about 1.9 per 1000 live births and 0.6 per 1000 live births 
for culture-proven cases of early-onset GBS sepsis.
Neonatal GBS disease in 1997-1998 45
These fi gures could be an underestimation because of unrecognised cases, cases that had 
been treated by intrapartum antibiotics and cases of fetal death because of GBS-infection. 
The fi gure of 0.6 per 1000 live births for culture proven cases of early-onset GBS sepsis is 
in accordance with the reported incidence in some other European countries, but lower 
than the incidence in the USA before formal guidelines for the prevention of early-onset 
GBS disease were introduced.1-4 The corrected incidence of neonatal early-onset GBS 
disease (sepsis plus probable sepsis) in the Netherlands equals the former incidence 
of blood culture proven early-onset GBS sepsis in the USA only. This difference can 
probably be explained by differences in the epidemiology of GBS disease, differences 
in diagnostic procedures used and the extent of the use of antibiotics during pregnancy. 
Cases of early-onset probable sepsis may be under-reported more easily in the DPSU (fi g. 
2) and it can be assumed that these cases are generally less severe than proven cases. 
Therefore, the incidence of early-onset GBS-disease can be regarded as a reasonable 
fi gure for the more severe end of the spectrum of GBS-disease, with uncertainties with 
respect to the less severe cases. The effect of preventive measures should probably be 
evaluated on the basis of the incidence of the proven cases. 
In the Netherlands, the use of antibiotics during pregnancy and labour had already started 
to rise by the time of the introduction of formal guidelines for the prevention of neonatal 
early-onset GBS disease in 1999 for other reasons, such as prevention of premature 
delivery. A prerequisite for adequate prophylaxis of GBS disease is that antibiotic 
treatment started at least 4 h before delivery. The drug of choice is penicillin G, to be 
administered in a dose of 2 million IU every 4 h until delivery. In our study, mothers of 
neonates with early-onset probable GBS-sepsis (36/190) were more often treated with 
antibiotics during labour than mothers of neonates with early-onset GBS-sepsis (12/157). 
However, owing to the lack of retrievable information on antibiotic treatment regimens, 
it is not known whether treatment was adequate in these cases. Maternal antibiotic 
treatment, especially inadequate prophylaxis, may lead to negative cultures in clinically 
septic neonates. We therefore strongly recommend registering cases of both neonatal 
early-onset GBS sepsis and early-onset probable GBS-sepsis.
The case-fatality rate for early-onset GBS disease in the Netherlands has decreased during 
recent decades from about 30% 12,13 to 5% found in this study for 1997-98. This fi gure is in
accordance with recent literature from the USA.6 The case-fatality rate in some other 
reports is higher, probably because of a more selected study-population.14 The cause of 
the decline in the case-fatality rate during the last 30 years is unknown, but may well 
result from improved neonatal care. As a signifi cant number of infants who die from GBS 
disease are preterm (6/16 in this study), further improvement of care for this category of 
patients may help to lower mortality from GBS disease. 
The majority of the infants with early-onset GBS-disease were born in hospitals despite 
the fact that about 30% of all deliveries in the Netherlands take place at home. Although 
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in 40% of the neonates who developed GBS disease, risk factors were absent and these 
infants would have been missed by a prevention program based on risk factors, the 
majority of these infants were observed in hospital for other reasons. This may have 
facilitated early recognition of symptoms followed by prompt treatment and prevention 
of death. As reported by others in the literature, recognition of the fi rst symptoms of 
early-onset GBS disease occurs within 48 h after birth in most cases.1 In our study, we 
found that, in 93% of the infants, symptoms were observed within 24 h after birth. From 
these data, we can conclude that a 24-48 h observation period is suffi cient to avoid late 
recognition of symptoms in infants at high risk of neonatal early-onset GBS disease 
without symptoms at birth. 
The results of our study confi rm that preterm delivery and prolonged rupture of the 
membranes are more frequent in cases of early-onset GBS disease and therefore can be 
used as indicators for risk of development of early-onset neonatal GBS disease as has 
been suggested before.9,10,15 The fact that early-onset GBS disease can cause serious illness 
is illustrated by the high percentage of patients (39% in the case of GBS sepsis and 25% in 
the case of probable GBS sepsis) who were treated with mechanical ventilation and many 
who needed treatment with inotropic drugs and/or volume expansion (50% in the case of 
GBS sepsis and 31% in the case of probable GBS sepsis). In our study, no follow-up data 
were available. However, long-term handicaps can be expected to be present in a certain 
number of patients. 
The results of this study show that, despite the signifi cant decline in the mortality rate 
of early-onset neonatal GBS disease, the incidence of this serious condition with high 
morbidity justifi es the introduction of guidelines for prevention.
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Abstract
Objectives To describe the epidemiology of neonatal GBS-disease over fi ve years (1997-
2001) in the Netherlands, stratifi ed for proven and probable sepsis and for very early (<12 
hr), late early (12 hr-<7d) and late (>7d) onset sepsis. To evaluate the introduction in 
1999 of guidelines for prevention of early-onset GBS disease based on risk factors.
Methods Cases were collected in co-operation with the Dutch Paediatric Surveillance Unit 
and corrected for under-reporting by the capture-recapture technique. 
Results The total incidence of proven early-onset and late-onset GBS sepsis was 0.43 and 
0.14 per 1000 live births respectively. That of probable early-onset and late-onset GBS 
sepsis was 1.4 and 0.02 per 1000 live births respectively. In 46% of the proven early-onset 
cases maternal risk factors were absent. Signifi cantly more infants with proven GBS sepsis 
were boys. In proven very early-onset GBS sepsis 64% of the patients were fi rst born 
versus 47% in the general population. After the introduction of guidelines the incidence 
of proven early-onset (<7 days) sepsis decreased signifi cantly from 0.54 per 1000 live 
births in 1997-1998 to 0.36 per 1000 live births in 1999-2001. The incidence of late-onset 
sepsis remained unchanged. The incidence of meningitis and the case fatality rate did not 
decrease.
Conclusion After introduction of risk factor based prevention guidelines, the decrease 
of the incidence of proven early-onset (<7 days) GBS sepsis was limited. We therefore 
recommend adaptation of the Dutch GBS prevention guidelines with inclusion of 
screening for GBS carriership to cover more cases without risk factors.
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Introduction
Early-onset GBS infection can be prevented by intrapartum chemoprophylaxis.1 In 
Europe, prevention strategies were developed later than in the USA.2 In January 1999, the 
Dutch Paediatric Association and the Society of Obstetrics and Gynaecology introduced 
such guidelines based on risk factors. Chemoprophylaxis is recommended in case of a 
previous infant with GBS disease and in heavily colonised mothers. When intrapartum 
fever (>38.0°C) is present antibiotics are administered. In case of labour before 37 weeks 
or prolonged rupture of membranes (≥ 18-24 hours), screening for GBS carriership is 
performed, followed by chemoprophylaxis when the culture is positive.3 
The aim of this study was to evaluate GBS disease in the fi rst three months of life 
during 1997-2001 in the Netherlands and to compare the periods before and after the 
introduction of prevention guidelines.
Methods
For data collection, we co-operated with the Dutch Paediatric Surveillance Unit (DPSU). 
This unit co-ordinates an ‘active’ case-reporting structure to facilitate the investigation of 
infrequent paediatric diseases. Its methodology involves the monthly mailing of a card 
containing a variable menu of 10 conditions to all clinically active paediatricians. During 
1997-2001, neonatal GBS disease was included in the DPSU surveillance. Respondents 
were requested to report both proven and probable cases of GBS disease during the 
fi rst 3 months of life diagnosed in the preceding month. The DPSU forwarded the 
names of the reporting paediatricians to one of the authors (MTS). She then sent them a 
questionnaire to collect clinical, microbiological and biochemical data of both mothers 
and infants. 
Because of the possibility of incompleteness of the data reported to the DPSU, the results 
were corrected for under-reporting. For this, we used the capture-recapture technique to 
estimate the number of cases missed by the DPSU surveillance. This technique uses the 
total number of cases reported to each of two independent sources. The corrected total 
number of cases can be calculated from the numbers reported by each source and the 
overlap between them.4 The second independent source we used was the response after 
a call for patients, published in a national parent’s magazine from 1997 through 2001 
in which parents were asked to report to one of us (GdJ) if they had a child with GBS 
disease during the fi rst 3 months of life. We checked whether individual cases reported by 
parents had been reported to the DPSU by paediatricians. If not, relevant information was 
requested from the paediatrician involved. Finally the case was classifi ed as proven or as 
probable GBS sepsis or it was discarded, similar to the procedure for the cases reported 
52 Chapter 5
to the DPSU. We estimated the level of completeness of reporting of GBS meningitis to 
the DPSU in the same way. The data of the microbiology laboratory of the Academic 
Medical Centre in Amsterdam as the national reference laboratory for bacterial meningitis 
were used as the second source for the cases of GBS-meningitis. 
In order to study the relevance of the time between birth and the onset of the fi rst 
symptoms we stratifi ed the patients into three groups : “very early-onset” (< 12 hours), 
“late early-onset” (12 hours -< 7 days) and “late-onset” (7-90 days) neonatal GBS 
infection. 
Neonates with proven and with probable GBS sepsis were analysed separately. The 
diagnosis of proven GBS sepsis was based on the simultaneous presence of clinical 
features of septicaemia, abnormal results of laboratory investigations (leucocytosis or 
leucopenia, granulocytopenia, shift to the left, thrombocytopenia, elevated CRP) as well 
as a positive GBS culture of blood and/or cerebrospinal fl uid (CSF). The diagnosis of 
probable GBS sepsis was based on the presence of the same clinical and laboratory 
features and the isolation of GBS from various sites, but without positive blood or CSF 
culture.5
Four obstetric risk factors of early-onset GBS disease were documented: delivery before 
37 weeks, ruptured membranes for ≥ 18 hours, intrapartum fever (>38.0 0 C) and previous 
delivery of a child with GBS disease.6,7 The risk factor heavy maternal GBS colonisation 
was left out of the analysis because in the Netherlands urine cultures are not performed 
routinely. 
The following data were collected as well: gender, gestational age, parity, intrapartum 
antibiotic treatment, multiple pregnancy, mode of delivery, meconium-staining of 
amniotic fl uid, place of delivery, age when fi rst symptoms occurred, meningitis and fatal 
outcome. We expressed the effect of the availability of guidelines on the incidence of 
GBS disease in terms of Rate Ratio (RR) and 95% confi dence intervals (CI). P-values < 
0.05 were considered signifi cant. The study was approved by the Ethics Committee of the 
University Medical Centre Nijmegen.
Results
Incidence of GBS disease
Over the whole period 1997-2001 the corrected incidence of proven early-onset and 
late-onset GBS sepsis was 0.43 and 0.14 per 1000 live births respectively. Of probable 
early-onset and late-onset GBS sepsis the corrected incidence was 1.4 and 0.02 per 1000 
live births respectively.
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Over the 2-year period 1997-1998, before the introduction of guidelines, 378 cases 
reported to the DPSU were included in the study. Of these, 184 were proven GBS sepsis 
and 194 were probable GBS sepsis (table 1). 
In the 3-year period after the introduction of the guidelines (1999-2001) 564 cases 
reported to the DPSU were included in the study. Of these, 246 were proven GBS sepsis 
and 318 were probable GBS sepsis (table 1). 
In 1997-1998, parents reported 27 cases of proven and 22 of probable GBS sepsis. Of 
these, 19 with proven and 8 with probable GBS sepsis were also reported to the DPSU. 
Therefore, the DPSU captured only 70% of proven and 36% of probable GBS sepsis. 
In 1999-2001, parents reported 33 cases of proven and 51 of probable GBS sepsis. Of 
these, 27 with proven and 19 with probable GBS sepsis were also reported to the DPSU. 
Therefore, the DPSU captured only 82% of patients with proven and 37% of patients with 
probable GBS sepsis.
After correction for underreporting, the decrease of the incidence of very early-onset GBS 
sepsis from 0.38 per 1000 live births in 1997-1998 to 0.28 per 1000 live births in 1999-2001 
was not statistically signifi cant (table 1). Total proven early-onset GBS sepsis, corrected 
for underreporting, decreased signifi cantly from 0.54 per 1000 live births to 0.36 per 1,000 
live births (table 1). There was no decrease in the corrected incidence of total probable 
early-onset GBS sepsis, respectively 1.3 and 1.4 per 1000 live births (table 1). In the small 
category of late-onset GBS sepsis, there was no decrease in the corrected incidence of 
proven cases. 
Table 1. Corrected incidence of proven and probable neonatal GBS sepsis before (1997-1998) and after (1999-2001) the 
introduction of guidelines for prevention of early onset GBS disease in the Netherlands.
DPSU
Reported cases
Corrected incidence*
Per 1000 live births (95% CI) RR (min-max)**
1997/98 1999/01 1997/98 1999/01
Live births 391,851 608,665
Proven GBS sepsis  
Early-onset 157 196 0.54 (0.42-0.67) 0.36 (0.32-0.41) 0.67 (0.48-0.98)
Very-early 128 140 0.38 (0.30-0.46) 0.28 (0.22-0.34) 0.74 (0.48-1.13)
Late-early 29 56 0.13 (0.07-0.19) 0.09*** 0.69 (0.47-1.30)
Late-onset 27 50 0.14 (0.07-0.27) 0.14 (0.06-0.23) 1.0 (0.22-32.9)
Probable GBS sepsis
Early-onset 190 313 1.3 (0.61-2.1) 1.4 (0.9-1.9) 1.08 (0.43-3.11)
Very-early 159 257 0.99 (0.44-1.53) 1.1 (0.65-1.52) 1.11 (0.42-3.45)
Late-early 31 56 0.4 (0.0-1.1) 0.3 (0.06-0.53) 0.75 (0.05-53.0)
Late-onset 4 5 0.01 0.02 (0.0-0.04) 2.0 (0.0-4.0)
* Corrected for underreporting to the DPSU through capture recapture technique, this may cause data discrepancies.
** RR(Rate Ratio): min-max calculated with lowest and highest estimates of incidence
*** no underreporting for this category.
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Incidence of GBS meningitis
In 1997-1998 and 1999-2001 respectively, a total of 29 and 57 patients with proven GBS 
meningitis were reported to the reference microbiology laboratory. Since 16 and 36 
of these were also reported to the DPSU, the DPSU captured only 55% of the cases of 
GBS meningitis in 1997-1998 and 63% of them in 1999-2001. Therefore, the corrected 
incidence of proven GBS meningitis in the Netherlands in these two periods was 0.14 
(95% CI 0.11-0.17) and 0.17 (95% CI 0.15-0.19) per 1000 live births respectively and in the 
total 5 year period 0.16 (95% CI 0.14-0.17) per 1000 live births. The proportion of patients 
with GBS meningitis was clearly related to the time of onset of GBS disease and increased 
from 6% if the onset was < 12 hours to 53% if the onset was > 7 days after birth (table 2). 
Table 2. Reported incidence of proven GBS meningitis in 1997-2001.
1997-2001 N
Lumbal puncture performed Lumbal puncture positive Proven meningitis (%)
Reported to DPSU
Early-onset 353 132 (37%) 55 (42%) 55/353 (16%)
Very-early 268 79 (29%) 17 (22%) 17/ 268 (6%)
Late-early 85 53 (62%) 38 (72%)  38/85 (45%) 
Late-onset 77 47 (61%)* 41 (87%) 41/77 (53%)
* Cochran-Armitage test for trend with time of onset P < 0.0001
Case fatality rate
In the whole 5-year period, the case fatality rate (CFR) of proven early and late-onset 
GBS-sepsis was 8% and 5% respectively. The CFR of proven early-onset GBS sepsis was 
7% versus 9% in the two periods and the mortality was similar (0.028 / 1000 live births). 
The CFR of proven late-onset GBS sepsis was 7% in the fi rst and 4% in the second 
period (table 3). The CFR of probable early and late-onset GBS sepsis was 2% and 0% 
respectively. In a more selected (NICU) population, the CFR of proven early-onset GBS 
sepsis has decreased in the past 25 years from about 62% to about 13% (table 3). 
Timing of onset of GBS disease 
In 1997-1998, in 70% of the patients (128/184) and in 1999-2001, in 57% of the patients 
(140/246) with proven GBS infection, the fi rst symptoms were observed within 12 
hours after birth. In respectively 85% (157/184) and 80% (196/246) of the cases, the fi rst 
symptoms occurred within 7 days after birth.
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Table 3. Case fatality rate of proven cases of GBS sepsis (<3 months) in the last three decades 
Early-onset GBS sepsis Late-onset GBS sepsis
Remington and Klein8
1982 55% 23%
1995 10- 15% 2- 6%
2001 5- 10% 2- 6%
The Netherlands (All hospitals)
1997- 1998 11/ 157 (7%) 2/ 27 (7%)
1999- 2001 17/ 196 (9%) 2/ 50 (4%)
1997- 2001 28/ 353 (8%) 4/ 77 (5%)
The Netherlands (NICU’s)
1977-19819 13/ 21 (62%) 4/5 (80%)
1985-199310 18/ 78 (23%) 2/4 (50%)
1994-199611 21/ 66 (32%) 3/7 (43%)
1997-2001 (this study*) 14/ 111 (13%) 2/19 (10%)
* Case fatality rate in the same 8 NICU’s in the Netherlands as those in 1994-1996
Risk factors
In patients with proven very early-onset (< 12 hours) GBS disease, the presence of the 
risk factor preterm delivery was signifi cantly lower in 1999-2001 (40/140; 29%) compared 
to 1997-1998 (54/128; 42%). The prevalence of the risk factors prolonged rupture of 
membranes, intrapartum fever and a previous child with GBS disease did not change in 
both periods. In the period 1997-2001 the presence of the risk factor preterm delivery 
was 3-5 times higher in case of proven GBS sepsis than in the Dutch population (table 
4). Only in proven very early-onset GBS sepsis, the presence of prolonged rupture of 
membranes and intrapartum fever was about 3 times higher (table 4). In 46.7 % of all 
patients with proven early-onset GBS sepsis none of the four risk factors was present. 
Table 4. Prevalence of risk factors in proven GBS sepsis, in 1997-2001 in the Netherlands
Proven GBS sepsis
Very-early onset Late-early onset Late-onset Dutch population*
n
268 %
n
85 %
N
77 % %
Preterm delivery (<37 weeks) 94 35 17 20 30 39  7.6
PROM (≥ 18 hrs) 91 34 14 16 9 12 10.8
Intrapartum fever
( > 38.0°C)
52 19 0 0 2 3  5.7
Previous child with
GBS disease
2 1 1 0 2 3  < 0.17 **
No risk factor 109 41 55 65 37 48  >80
*best estimates from several sources ( f.e. CBS = Statistics Netherlands and Prismant (LVR) = Institute for health care management). 
**the probability of having a previous child with early-onset GBS is calculated by multiplying 3 cases per 1000 live births by 55.2%, the 
percentage of multiparous infants.
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Characteristics of infants and mothers in proven gbs sepsis
In table 5 the patient characteristics over the period 1997-2001 are shown because there 
were no differences between 1997-1998 and 1999-2001.
Gender: of the 430 infants with proven GBS sepsis, 57% were boys and of the 512 infants 
with probable GBS sepsis, 300 (59%) were boys. In the general population, this is 51.1% 
(p<0.05) (table 5). There was no gender difference in the GBS early and late meningitis 
cases or in the early and late fatal cases. 
Birth order: of the 268 infants with proven very early-onset GBS sepsis 171 (64%) were 
fi rst borns and of the 415 infants with probable very early-onset GBS sepsis 243 (59%) 
were fi rst borns, versus 47% in the general population ( p<0.0001). 
Other characteristics: none of the mothers of infants with proven late early-onset sepsis 
received antibiotics during delivery. The group of patients with proven very-early GBS-
sepsis contained two times more twins, caesarean section and meconium stained amniotic 
fl uid than expected and most of them were born in the hospital (85%). 
Table 5. Characteristics of mothers and infants in proven GBS sepsis in 1997-2001
1997-2001
Very-early onset sepsis
(n = 268)
Late-early onset sepsis
(n =85)
Late-onset sepsis
(n = 77)
Total Dutch population *
Male 158 (59%) 41 (48%) 45 (58%) 51.1%
First born 171 (64%) 39 (46%) 28 (36%) 47.0%
Gestation (>37 w) 174 (65%) 68 (80%) 47 (61%) 92.4%
Twin 19 (7%) 2 (2%) 10 (13%) 3.5%
Caesarean section 55 (20%) 12 (14%) 13 (17%) 10.5%
Meconium-stained amniotic ﬂ uid 42 (16%) 8 (9%) 2 (3%) 7.6%
Home delivery
Hospital delivery
20 (7%)
228 (85%)
21 (25%)
56 (66%)
15 (19%)
56 (73%)
+/- 30%
+/- 70%
*best estimates from several sources ( f.e. CBS = Statistics Netherlands and Prismant (LVR) = Institute for health care management). 
Discussion
We found that the incidence (corrected for 77% response) of proven neonatal GBS sepsis 
during 1997-2001 in the Netherlands was 0.56 per 1000 live births. For probable GBS 
sepsis the incidence (corrected for 37% response), was 1.38 per 1000 live births. We 
collected data of patients with probable disease as well, because most of them probably 
have had GBS sepsis and the total incidence of proven GBS sepsis therefore would be 
higher. 
Early-onset disease usually is defi ned by the occurrence of its fi rst symptoms in the fi rst 
seven days after birth. We subcategorised early-onset GBS sepsis in “very early-onset”(< 
12 hours) and “late early-onset” (12 hours-< 7 days). With this approach, we found that 
in 76% (268/353) of proven early-onset cases fi rst symptoms occurred within 12 hours. 
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In these patients, the risk factors prolonged rupture of membranes and intrapartum fever 
were present more frequently. In none of the patients with late early-onset disease the 
risk factor intrapartum fever was present. Mothers of patients with proven very early-
onset GBS sepsis were more often primigravid. Because of these reasons, we consider 
it appropriate to distinguish very early-onset (<12 hours) from early-onset GBS disease. 
The difference in birth order may partly be due to the longer duration of the fi rst 
delivery.12 Following the introduction of the guidelines, there was a signifi cant decrease 
of the incidence of proven early-onset GBS sepsis. This can be explained by the vertical 
transmission of early-onset GBS sepsis. The incidence of late-onset GBS sepsis remained 
unchanged, because of nosocomial acquisition.13,14 
The overall effect of the Dutch guidelines is disappointing, since the decrease of the 
incidence of proven early-onset GBS sepsis was limited and mortality, meningitis and 
probable sepsis did not decrease. In the USA the incidence of proven early-onset 
GBS sepsis was higher and varied from 1.1-3.7 per 1000 live births. In one study the 
incidence dropped from 1.7 per 1000 live births 1993 to 0.6 per 1000 live births in 1998 
after the introduction of prevention guidelines in 1996.15,16 The US guidelines at that 
time recommended a strategy based on screening or on the presence of risk factors. 
The Dutch guidelines are based on recognition of risk factors. In order to limit antibiotic 
prophylaxis during delivery, screening is performed fi rst in case of labour before 37 
weeks and/or prolonged rupture of membranes, followed by antibiotic prophylaxis in 
case of a positive culture. In case of delivery before the culture result is available, the 
obstetrician should decide about prophylaxis.3 Therefore the Dutch guidelines can be 
expected to have a limited effectiveness since in case of preterm labour and/or prolonged 
rupture of membranes cases can be missed because of the delay of obtaining culture 
results. Furthermore, in about 40-50% of all cases of early-onset GBS-sepsis no maternal 
risk factors are present.17 In the USA, it was shown that the screening strategy is more 
effective than the risk factor based strategy.18,19
Since meningitis occurs more often in late-onset GBS disease and chemoprophylaxis 
is effective to prevent early-onset GBS disease, the incidence of meningitis did not 
decrease. Moreover, there is underreporting of meningitis because in unstable (preterm) 
newborns, lumbar puncture frequently is not performed. The CFR of GBS disease 
decreased dramatically in the last 25 years and in proven neonatal GBS sepsis it was 
less than 10% in this study. The CFR in proven GBS sepsis in a more selected (NICU) 
population is higher; in our study population it was 13%, which is much lower than three 
decades ago.20 The decline of the CFR of GBS sepsis may be attributed to improvement 
of neonatal care, antibiotic prophylaxis and change of the virulence of the GBS-bacteria.21 
The CFR and the mortality of proven early-onset GBS sepsis did not decrease further 
after the introduction of the guidelines, partly because the administration of antibiotics is 
primarily for prevention and not for treatment of GBS disease. 
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Of all 77 infants with proven late-onset GBS disease, 31 were born before 37 weeks. This 
confi rms that preterm delivery is the most important perinatal risk factor in late-onset 
disease.22 
More infants with proven GBS-sepsis were boys. In two other Dutch studies this gender 
difference was described as well.9,11 Most of the patients with very early-onset sepsis were 
born in the hospital (85%), which is in contrast to the fact that 65% of all deliveries are 
performed in the hospital. The explanation might be that in the Netherlands pregnant 
women with risk factors usually are referred to a hospital. Fifty-six infants with proven 
GBS sepsis were born at home and in only 9 (16%) of them one of the four risk factors 
was present.
Because the effectiveness of the Dutch risk factor based guidelines for prevention of 
neonatal GBS disease is limited, we recommend adaptation of these guidelines to cover 
more cases in which risk factors are absent.
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Summary
To evaluate the implementation of the Dutch risk factor based guidelines for prevention 
of GBS disease as issued in 1999, questionnaires were sent in 1997 and in 2000 to 120 
gynaecologists. In addition, by taking a stratifi ed sample of 10% of Dutch hospitals, actual 
practice was studied. In 1997, 89% of the gynaecologists reported to have a local protocol 
for intrapartum administration of antibiotics. In 2000, all gynaecologists reported to be 
familiar with the guidelines. Intrapartum administration of antibiotics increased from 
1.0% in 1997 to 5.9% in 2000. Amoxicillin/clavulanic acid was used mostly but usually 
inadequately. It is concluded that the implementation of the Dutch risk-factor-based 
guidelines resulted in a signifi cant increase in the use of intrapartum antibiotics; however, 
there still is a clear discrepancy between the ‘physicians’ owns presumed and actual 
compliance with the guidelines for the prevention of neonatal GBS disease.
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Introduction 
Neonatal GBS infection may be prevented by intrapartum antibiotic prophylaxis in 
women at increased risk for transmitting the disease.1 In 1996, the US Center for Disease 
Control and Prevention recommended either a screening or a risk based strategy.2 In 
1999, the Dutch Society of Obstetrics and Gynaecology and the Paediatric Association 
of the Netherlands issued risk factor based guidelines (fi gure 1). Antibiotic prophylaxis 
was recommended in case of a previous infant with GBS disease, in heavily colonized 
mothers and in case of intrapartum fever (>38.0°C). In case of labour before 37 weeks or 
prolonged rupture of membranes (≥ 18-24 hours), screening for GBS carriership should 
be followed by prophylaxis if the culture is positive (fi gure 1).3 The incidence of proven 
early-onset (<7 days) GBS sepsis decreased signifi cantly from 0.54 per 1000 live births in 
1997-1998 to 0.36 per 1000 live births in 1999-2001 (Unpublished data). The aim of this 
study was to evaluate intrapartum administration of antibiotics and the implementation of 
the Dutch guidelines for prevention of neonatal Group B Streptococcal disease. 
Methods
Surveys among gynaecologists were performed in 1997 on the presence of a local 
prevention protocol and in 2000 on the familiarity with the nationwide prevention 
guidelines. In both years, we sent a questionnaire to a random sample of 120 Dutch 
gynaecologists. The sample was stratifi ed for type of hospital. General hospitals are 
smaller hospitals without obstetric residents. Teaching hospitals are affi liated to university 
hospitals for training of obstetric residents. Questions were asked about total number of 
deliveries and their familiarity to two risk factors for GBS disease: delivery <37 weeks and 
prolonged rupture of membranes (> 24 hours).
The fi rst questionnaire (1997), contained additional questions regarding the presence 
of a protocol for the prevention of GBS disease and the reasons for administering 
antibiotics durante partu. The second questionnaire (2000), contained additional 
questions on whether they were familiar with the nationwide GBS prevention guidelines 
and whether they complied with them. Furthermore, in both years we took a stratifi ed 
sample of 10% of all hospitals to study actual practice. In each hospital, 100 deliveries 
were randomly selected from the delivery ward log book. Medical records were used to 
collect data on four of fi ve risk factors for GBS disease (premature delivery (<37 weeks), 
prolonged rupture of membranes (> 24 hrs), intrapartum fever (>37,8°C), or a previous 
child with GBS disease). The fi fth risk factor, “heavily colonized” mother, presenting 
as GBS bacteriuria, was omitted because urine cultures are not performed routinely. 
Other aspects investigated were cultures for GBS, intrapartum use of antibiotics and 
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Pregnancy
Prevention strategy of early onset GBS disease in the Netherlands
Risk factor neonatal early onset GBS sepsis
• Preterm
• Prolonged rupture of 
membranes
• GBS bacteriuria during 
current pregnancy
• Previous child with GBS 
disease
• Maternal fever during 
delivery
N Y Y Y
GBS diagnostics Lab for infection without delay
No GBS carrier GBS carrier *
No antibiotic 
prophylaxis during 
delivery
Antibiotic
prophylaxis during 
delivery
Antibiotics,
without delay
Adequate Not Adequate
Symptoms 
of infection
< 35 wks > 35 wksNo special 
measures
• Culture of ear and 
nasopharynx
• 48 hrs observation
• Culture of ear and 
nasopharynx
• 48 hrs observation
•Culture of blood ,CSF, ear 
and nasopharynx
•treat as neonatal sepsis
* In case of delivery before receiving the results of cultures the obstetrician should decide 
about antibiotic prophylaxis, based on the severity of the risk factor(s)
*  In case of delivery before receiving the results of cultures the obstetrician should decide about antibiotic prophylaxis, based on the severity of 
the risk factor(s)
Figure 1. Prevention strategy of early onset GBS disease in the Netherlands
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the condition of the newborn. In multiple births, only the fi rst newborn was included. 
Newborns that receive antibiotics after day 3 and those born before 25 weeks of gestation 
were excluded.
Adequate antibiotic prophylaxis was defi ned as intravenous prophylaxis with 5 million IU 
penicillin G or 2 g amoxicillin 4 h before birth followed by 2.5 million IU penicillin or 1 g 
amoxicillin every 4 h until delivery; furthermore at least two doses must be administered 
before delivery.
On both occasions 120 gynaecologists were sent a questionnaire. In 1997: 24 in 8 
university hospitals, 29 in 28 teaching hospitals and 67 in 99 general hospitals. In 2000: 27 
in 8 university hospitals, 37 in 30 teaching hospitals and 56 in 75 general hospitals.
The hospital sample for the study on actual practice consisted of 10% of all hospitals. 
Since this number of hospitals had changed, 15 hospitals (3 university, 5 teaching and 7 
general) were visited in 1997 and 12 hospitals (2 university, 5 teaching and 5 general) in 
2000. None of them was visited twice. In the Netherlands, approx. 30% of all deliveries 
are home deliveries and 70% are hospital deliveries of which 8% take place in university, 
30% in teaching and 62% in general hospitals. 
Data-analysis
As we stratifi ed our sample, we corrected all estimates for sampling frequency by 
multiplying the hospital type-specifi c estimates with the inverse of the sampling fraction. 
Then averaging over all hospitals will yield an estimate that should apply to the 
Netherlands as a whole. 
Results
Questionnaires 
In 1997, 98 of the 120 questionnaires were returned. Eighteen gynaecologists did not 
complete the questionnaire for the following reasons: 13 were not working as an 
obstetrician and 5 refused to participate. As a result, 80 questionnaires were used for the 
1997 analysis. In 2000 76 of the 120 gynaecologists returned the questionnaires: 16 from 
university, 25 from teaching and 35 from general hospitals. Eight gynaecologists did not 
complete the questionnaire, since they were not working as an obstetrician. Therefore, 68 
questionnaires were used for the 2000 analysis.
In 1997, all 12 gynaecologists from a university hospital, 20 out of 21 from teaching 
hospitals and 39 out of 47 from general hospitals reported that they used a protocol for 
intrapartum antibiotic prophylaxis. The various indications are listed in table 1. The main 
indication was intrapartum maternal fever.
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Table 1. Availability of a protocol and indications for intrapartum administering antibiotics in 1997 per type of hospital
General hospital
N = 47
Teaching hospital
N = 21
University hospital
N = 12
Protocol for intrapartum 
administering antibiotics
N % N % N %
39 83 20 95 12 100
Indications :
Intrapartum maternal fever 38 81 19 90 12 100
Increased CRP 12 25.5 1 4.7 3 25
Leucocytosis 12 25.5 4 19 2 16.7
Foetal tachycardia 23 48.6 10 47 8 67
Cystitis 28 59.5 17 80.9 12 100
Endocarditis prophylaxis 36 76.6 20 95 12 100
Preterm delivery 2 5.1 3 14.3 2 16.7
In 2000, all 68 gynaecologists were familiar with the nationwide Dutch guidelines for 
prevention of GBS disease. In the university hospitals fi ve of the eight gynaecologists 
reported that in their clinic there was consensus on these guidelines and four of them 
reported that most women were treated accordingly. Three gynaecologists from university 
hospitals reported that in their clinic there was no consensus on the guidelines because 
they were not clear (n=1), had not been discussed (n=1) or were not correct (n=1).
In the teaching hospitals 23 of 25 gynaecologists reported that there was consensus on 
the guidelines and 19 of them reported that most women in their hospital were treated 
accordingly. Two gynaecologists from teaching hospitals reported that in their clinic there 
was no consensus on the guidelines since they were not clear (n=1) or not practical 
(n=1).
In the general hospitals 34 of 35 gynaecologists reported that there was consensus on 
the guidelines and 23 of them reported that most women were treated accordingly. One 
reported that there was no consensus in his unit because the guidelines were unclear.
Medical records
In 1997 we visited 15 hospitals. The sample population consisted of 1500 pregnant 
women. Five records were excluded because information was incomplete. The number 
of valid records was 1495, 300 (20%) from university, 498 (33%) from teaching and 697 
(47%) from general hospitals. 
In 2000 we visited 12 hospitals. The sample population consisted of 1200 pregnant 
women. Six records were excluded because information was incomplete. The number 
of valid records was 1194, 200 (17%) from university, 499 (42%) from teaching and 495 
(41%) from general hospitals.
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Prevalence of risk factors
The prevalence of preterm delivery in 1997 and 2000 was higher in the university than 
in the general and teaching hospitals, because of regionalisation of high risk prenatal 
care in the Netherlands. For unknown reasons in 1997, all hospitals showed an increased 
prevalence of PROM compared to fi gures from the Dutch population. In most women 
in 1997 and 2000 no risk factors were present. The estimated percentage for the Dutch 
population, after correction for sampling fraction of hospital type, was about 80% (table 2).
Table 2. Prevalence of risk factors for GBS disease in the study population and the general Dutch population in 1997 and 2000
General hospital Teaching hospital University hospital Dutch population this study * 
other sources**
1997 N = 697 N = 498 N = 300
Risk factors:
Preterm delivery (<37 weeks) 84 12.0% 70 14.0% 74 24.6% 9.6% 7.6%
Prolonged rupture of 
membranes (> 24 hours)
153 22.0% 108 21.7% 44 14.7% 15.0% 10.8%
Maternal fever (≥ 37,8 °) 2 0.3% 6 1.2% 13 4.3% 0.6% 5.7%
Previous child with GBS 1 0.1% 2 0.4% - - 0.15% <0.17%
No risk factor 486 69.7% 336 67.5% 190 63.3% 77.9% >80%
2000 N = 495 N = 499 N = 200
Risk factors:
Preterm delivery (<37 weeks) 42 8.5% 43 8.6% 37 18.5% 6.5% 7.6%
Prolonged rupture of 
membranes (> 24 hours)
66 7.5% 96 19.2% 29 14.5% 10.6% 10.8%
Maternal fever (≥ 37,8 °) 25 5.0% 13 2.6% 12 6% 3.1% 5.7%
Previous child with GBS 4 0.8% 0 2 0.01% 0.4% < 0.17%
No risk factor 376 76.0% 369 73.9% 132 66% 82.3% >80%
*Estimated proportion for the Dutch population corrected for the sampling fraction per hospital type, assuming that no deliveries with risk 
factors occurred at home
**best estimates from several sources ( f.e. CBS = Statistics Netherlands and Prismant (LVR) = Institute for health care management). 
Cultures
In 2000, the number of cultures taken was higher in all types of hospitals than in 1997, 
especially in preterm delivery and PROM. However, the frequency was still very low, as 
the weighted proportion was 16% in 1997 and 30% in 2000. In 1997, no risk factor was 
present in 39 of the 126 cases in which cultures were taken. In 3 of the 19 GBS positive 
cultures no risk factors were present. 
In 2000, no risk factors were present in 85 of the 202 cases in which cultures were taken.. 
In 15 of the 29 GBS positive cultures no risk factors were present (table 3). 
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Table 3. Number of women in which cultures were taken in 1997 and in 2000
N
General  hospital Teaching hospital University hospital Hospital deliveries 
Weighted proportion** 
1997 2000 1997 2000 1997 2000 1997 2000
697 495 498 499 300 200
Number of women in which cultures 
were taken
28
4%
68
13.7%
62
12.4%
76
15.2%
36
12%
58
29% 7.2% 15.4%
1. Cultures taken in case of preterm 
delivery or PROM 
13/174
7.5%
15/88
17%
31/140
22.1%
33/111
30%
20/83
24%
28/50
56% 48.2% 16.7%
2. Cultures taken in case of preterm 
delivery and PROM
5/25
20%
8/10
80%
10/17
59%
11/14
79%
8/15
53%
8/8
100% 17.7% 8.2%
3. Cultures taken in case of neither 
preterm delivery and/or PROM
10/498
2%
45/397
11.3%
21/341
6.2%
32/374
8.6%
8/202
4.0%
22/142
15.5% 34.1% 43.7%
Number of women with indication 
for culture *
199 98 157 125 98 58
Room for improvement 181
91%
75
76.5%
116
73.8%
81
64.8%
70
71.4%
22
37.9% 84% 70%
GBS positive culture 3/28
10.7%
16/68
23.5%
9/62
14.5%
4/76
5.3%
7/36
19.4%
9/58
15.5% 12.5% 17.4%
* Women with the risk factor preterm delivery and /or PROM
** Weighted proportion = the estimated proportion corrected for the sampling fraction of the hospitals
Table 4. Intrapartum antibiotics and indications for administration in 1997 and in 2000
 
N
General hospitals Teaching hospitals University hospitals Hospital deliveries 
Weighted  Proportion* 
1997 2000 1997 2000 1997 2000 1997 2000
697 495 498 499 300 200
The percentage of women with 
intrapartum antibiotics
3
(0.4%)
22
(4.4%)
5
(1%)
31
(6.2%)
18
(6%)
33
(16.5%) 1.04% 5.9%
Indications:
1. Preterm delivery (< 37 wks) 0 3 0 7 1 13 0.02% 1.3%
2. Prolonged rupture of membranes 
(> 24 hours)
2 7 2 15 5 8 0.43% 2.1%
3. Maternal fever (≥ 37,8 °) 0 8 1 9 9 9 0.30% 1.9%
4. Previous child with GBS 0 2 0 0 1 1 0.03% 0.29%
5. GBS carrier 1 2 2 0 2 2 0.26% 0.33%
Antibiotics :
1. Penicillin 0 2 1 0 0 0 0.06% 0.25%
2. Amoxicillin/ Clavulanic acid 3 13 4 27 8 19 0.72% 4.01%
3. Other 0 7 0 4 10 14 0.27% 1.68%
* Weighted proportion = the proportion corrected for sampling fraction of the hospitals
Intrapartum administration of antibiotics 
The percentage of women that received intrapartum antibiotics increased in all types of 
hospital: in general hospitals from 0.4% to 4.4%, in teaching hospitals from 1.0% to 6.2% 
and in university hospitals from 6% to 16.5% in 1997 and 2000, respectively. Prolonged 
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rupture of membranes and maternal fever were the usual indications,. The antibiotic drug 
most frequently used was amoxicillin/clavulanic acid, whereas penicillin was rarely used 
(table 4).
Compliance of the Dutch guidelines in 2000
According to the Dutch guidelines, cultures should be taken in all pregnancies with 
preterm delivery and/or prolonged rupture of membranes (fi g. 1). In preterm delivery 
cultures were taken in respectively 31%, 51% and 68% of general, teaching and 
university hospitals. In case of prolonged rupture of membranes, cultures were taken in 
respectively 27%, 34% and 66% of general, teaching and university hospitals. According 
to the Dutch guidelines antibiotics should be given to all pregnant women with maternal 
fever or a previous child with GBS disease (fi g. 1). In case of maternal fever, women 
were treated with antibiotics in respectively 32%, 70% and 75% of general, teaching and 
university hospitals. In 18 of the 26 women receiving antibiotics, amoxicillin/clavulanic 
acid was used (3/18 women an antibiotic prophylaxis with amoxicillin/clavulanic acid 
was adequate). Penicillin was not used. In case of a previous child with GBS disease 
antibiotics were given to two of the four women in general hospitals and to one of the 
two women in the university hospitals. In all pregnancies for which antibiotic prophylaxis 
was indicated none of the woman was adequately treated with penicillin according to the 
Dutch guidelines. However, 20% was treated adequately with amoxicillin/clavulanic acid 
(table 5).
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Table 5. Compliance of the Dutch GBS prevention guidelines in 2000 
Risk factors General hospitals Teaching hospitals University hospitals
Preterm delivery 42 43 37
Cultures taken 13 (31%) 22 (51%) 25 (68%)
Antibiotic prophylaxis 3 (7%) 7 (16%) 13 (35%)
Penicillin 1 - -
Amoxicillin/ clavulanic acid - 7 8
Other 2 - 5
Adequate prophylaxis* (with Amoxicillin/clavulanic acid) 0 2 4
Prolonged Rupture of membranes 66 96 29
Cultures taken 18 (27%) 33 (34%) 19 (66%)
Antibiotic prophylaxis 7 (11%) 15 (16%) 8 (28%)
Penicillin 1 - -
Amoxicillin/ clavulanic acid 4 12 4
Other 2 3 4
Adequate prophylaxis* (with Amoxicillin/clavulanic acid) 1 3 3
Maternal fever 25 13 12
Cultures taken 10 (40%) 2 (15%) 7 (58%)
Antibiotic prophylaxis 8 (32%) 9 (70%) 9 (75%)
Penicillin - - -
Amoxicillin/ clavulanic acid 5 8 5
Other 3 1 4
Adequate prophylaxis* (with Amoxicillin/clavulanic acid) 1 1 1
Previous Child with GBS 4 0 2
Cultures taken 2 (50%) 0 (0%) 2 (100%)
Antibiotic prophylaxis 2 (50%) 0 (0%) 1 (50%)
Penicillin - - -
Amoxicillin/ clavulanic acid 2 - -
Other - - 1
Adequate prophylaxis* (with Amoxicillin/clavulanic acid) 0 0 0
* Adequate prophylaxis = intravenous prophylaxis with 5 million IU penicillin G or 2 g amoxicillin 4 h before birth, followed by respectively 2.5 
million IU penicillin or 1 g amoxicillin every4 h until delivery and at least two doses administered before delivery.
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Discussion
Dutch nationwide guidelines for prevention of early-onset GBS disease were implemented 
in 1999. Although most gynaecologists are familiar with these guidelines and have 
consensus on them in their unit, actual adherence to the guidelines is disappointing. 
The percentage of deliveries with antibiotic prophylaxis increased from 1.0% in 1997 to 
5.9% in 2000. However, in none of the pregnancies in which antibiotic prophylaxis was 
indicated penicillin, the drug of fi rst choice, was adequately used. 
One of the reasons to choose for the risk factor approach was that it was thought that the 
total incidence of proven and probable sepsis in the Netherlands was relatively low (0.9 
per 1000 live births3 ) compared to the incidence in the USA before the introduction of 
guidelines (1.1-3.7 per 1000 live births 4 ). Another reason was that approximately 30% of 
the Dutch deliveries take place at home. These pregnancies are monitored by midwives 
who should refer all women with risk factors for GBS disease to a hospital. 
Previously we found that the incidence of proven early-onset GBS sepsis after the 
introduction of the Dutch guidelines decreased signifi cantly from 0.54 per 1000 live births 
in 1997-1998 to 0.36 per 1000 live births in 1999-2000 (unpublished data). In the present 
study we evaluated whether this could have been attributed to the implementation of 
the Dutch guidelines by the gynaecologists. Since the preventive effect on GBS disease 
of intrapartum administration of antibiotics was well-known at that time, we performed 
a survey in 1997. Despite the fact that the most gynaecologists reported to have a local 
protocol for intrapartum administering antibiotics, the actual use of antibiotics was low. In 
2000, all gynaecologists reported that they were familiar with the nationwide guidelines 
and almost all of them reported to have consensus in their unit to use them. However, 
when we checked the medical records, the compliance with the guidelines revealed to be 
disappointing. That gynaecologists in questionnaires tend to exaggerate their compliance 
with guidelines was found previously. 5,6 Only a minority of the gynaecologists reported 
to have no consensus in their unit regarding the guidelines; three of them believed that 
they are unclear. The guidelines may be unclear indeed in case of preterm delivery 
and/or prolonged rupture of membranes. In these cases, a culture must be taken fi rst 
and in case of delivery before the culture results are available, the gynaecologist should 
make a decision regarding the use of antibiotic prophylaxis. This step was included in the 
guidelines to limit the use of antibiotics. The guidelines include a clear recommendation 
to take cultures in premature delivery and/or prolonged rupture of membranes, however 
in approx. 50% cultures were taken in 2000. In the guidelines antibiotic prophylaxis 
should be given in all cases of maternal fever and in cases of a previous child with GBS 
disease. However, only half of these women received antibiotics. Intrapartum antibiotic 
prophylaxis increased from 1.0% of all deliveries in 1997 to 5.9% in 2000. However, 
with reference to our guidelines we expected that in about 10-15% of the deliveries 
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intrapartum antibiotic prophylaxis should be given. Furthermore, adequate treatment with 
penicillin never took place when antibiotic prophylaxis was indicated. The minority was 
treated adequately with amoxicillin/clavulanic acid. It was shown before that penicillin as 
the drug of fi rst choice is used infrequently.7 In most cases, the broad spectrum antibiotic 
amoxicillin/clavulanic acid was used. This could result in selection of resistant gram-
negative organisms. 8 
A limitation in our study is the low response rate for the questionnaires in 2000. However, 
with the good response rate in 1997 and the use of a similar sample of hospitals in both 
years to study actual practice, we believe that the information from this study is reliable.
The fi rst possibility to increase the compliance to the guidelines would be to improve 
information to all gynaecologists, midwives, paediatricians, as well as parents. Another 
possibility is to change the guidelines. The effect of this risk factor based strategy may 
be limited since in preterm delivery and prolonged rupture of membranes cases may 
be missed due to delay in obtaining culture results. This delay could be limited to 
0.5-2 hours by using a PCR assay for rapid detection of GBS colonisation. 9,10 Another 
reason for a limited effect of the guidelines is that in about 40-50% of all cases of 
early-onset GBS-sepsis no maternal risk factors are present. 11 It was shown in the USA 
that the screening based strategy is more effective than the risk factor based strategy. 
12,13 However, there are also some adverse effects. In the Netherlands, GBS-carriership is 
about 15-20%. The use of antibiotic prophylaxis in such a large number of women could 
increase the risk of developing antibiotic resistance, as has already been reported for 
erythromycin and clindamycin, especially when a broad spectrum antibiotic is used. 14,15 
Another adverse effect could be an increasing incidence of adverse reactions to penicillin, 
including anaphylaxis.16 Furthermore, the choice for either risk factor or screening based 
strategy should also be cost-effective. In a recent cost-effectiveness analysis based on 
different decision models for the Dutch situation it was shown that both the risk based 
strategy and a combined screening and risk based strategy are reasonably cost-effective. 
17 After the data presented in this study became available the discussion was started in 
the Netherlands how to develop the most suitable prevention guidelines for the specifi c 
Dutch situation. 
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Abstract 
Background We studied the characteristics of strains isolated from neonates with Group 
B Streptococci (GBS) sepsis and meningitis in two periods, before (1997-1998) and after 
(1999) the introduction of antibiotic prophylaxis in the Netherlands. 
Methods 198 GBS strains were obtained from blood and /or cerebrospinal fl uid of 
neonates with GBS sepsis and/or meningitis. Serotyping, genotyping and susceptibility 
testing of the GBS strains was performed. 
Results There was no difference in the serotype distribution and genotype of GBS strains 
between the two periods. Serotype Ia and III were predominant in patients with early-
onset GBS sepsis and serotype III in patients with late-onset GBS sepsis and/or meningitis 
in the Netherlands. The GBS-strains were genetically heterologous and the clinical 
presentation of neonatal GBS disease was not associated with specifi c genotypes. There 
was no shift in susceptibility of the GBS-strains after the introduction of guidelines for 
antibiotic prophylaxis. 
Conclusion One year after the introduction of antibiotic prophylaxis in the Netherlands 
the serotype distribution and the genotype and the susceptibility patterns of the GBS 
strains did not change so far and penicillins remain drugs of fi rst choice to prevent and 
treat neonatal GBS disease. 
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Introduction 
Group B streptococci (GBS) remain an important cause of neonatal sepsis and meningitis, 
despite the introduction of preventive strategies. In the Netherlands, nationwide 
guidelines for prevention of early-onset GBS infection were introduced in January 1999. 
Thereafter we found a decline of the incidence of early-onset GBS sepsis from 0.54 per 
1000 live births in 1997-1998 to 0.36 per 1000 live births in 1999-2001 (unpublished data). 
In the past 25 years the case fatality rate of neonatal early-onset GBS sepsis has decreased 
from about 55% to 5-10% partly due to improved neonatal care.1 However, changes in the 
characteristics of the microorganism might have contributed as well. 
In this study we typed GBS-strains isolated in the Netherlands in 1997-1999 from 
patients with neonatal sepsis and meningitis and we studied the relationship between 
the clinical presentation of the disease and the serotype and/or genotype of GBS strains 
isolated before (1997-1998) and after introduction of antibiotic prophylaxis (1999). 
Finally, we determined the resistance patterns of the GBS-strains isolated before and 
after introduction of antibiotic prophylaxis in order to trace emergence of resistance and 
to evaluate whether the current antimicrobial approach in neonatal GBS disease in the 
Netherlands is still adequate.
Materials and Methods
Clinical data
Basic clinical data of 198 neonates hospitalised for GBS sepsis and/or meningitis in the 
Netherlands were obtained during the period 1997-1999. Additional clinical information of 
108 of them was available because they were included in an epidemiological study.2 (and 
unpublished data)
Strains
A total of 119 GBS strains in 1997-1998 and 79 GBS strains in 1999 were obtained from 
blood (N = 181) and/or CSF (N = 56) of neonates with GBS disease hospitalised in 51 out 
of the 93 neonatal and paediatric wards in the Netherlands. The strains were obtained 
from 22 Laboratories for Medical Microbiology and from the Netherlands Reference 
Laboratory for Bacterial Meningitis in the Academic Medical Centre Amsterdam.
Serology 
Serogrouping was carried out by the Streptex method. Serotyping was performed with the 
agglutination test using monospecifi c antisera against GBS serotype Ia, Ib, II, III, IV, V, VI, 
VII, VIII. 
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Genotyping 
Isolates were stored in Todd-Hewitt broth with 5% defi brinated sheep blood at – 80 °C 
until used for genetic characterisation. For pulsed-fi eld gel electrophoresis (PFGE), the 
isolates were treated essentially as described by Benson and Ferrieri.3 The chromosomal 
DNA was digested with 50 U SmaI for 3 hours at 25 °C and the DNA was separated 
with a contour-clamped homogenous electric fi eld (CHEF DR-II, Bio-Rad Laboratories, 
Richmond, California). Lambda phage concatemers were run simultaneously as a size 
marker. Pulse times were ramped from 2.2 to 54.2 seconds over 24 hours at 200V and 
14 °C. The gels were stained with ethidium bromide and PFGE patterns were compared 
visually.4 Controls were two epidemiological unrelated GBS strains (the NCTC-8181 T 
strain and a strain obtained from the RIVM).
Susceptibility testing
MIC’s were determined in duplicate by broth micro-dilution with IsoSensitest Broth 
(Oxoid CM 491, Haarlem, the Netherlands) supplemented with 2% lysed horse blood for 
fastidious microorganisms. The inoculum was prepared by the direct colony suspension 
method: colonies grown overnight on Columbia agar with 5% sheep blood were 
suspended in sterile saline up to a concentration of McFarland 0.5 turbidity standard. 
After dilution the fi nal inoculum was 4 x 105 cfu/ml. The antimicrobial agents tested 
were: penicillin, amoxicillin, ceftazidime, cefi xime, cefepime, meropenem, erythromycin, 
clarithromycin, vancomycin, teicoplanin, quinupristin-dalfopristin, ciprofl oxacin, 
trovafl oxacin and moxifl oxacin. Concentrations ranged from ≤ 0.03 to ≥ 128 mg/L for 
all drugs. The trays were incubated at 37°C and examined for growth after 24 h. Control 
strains were Escherichia coli ATCC 25922, Pseudo-monas aeruginosa ATCC 27853, 
Staphylococcus aureus ATCC 29213 and Enterococcus faecalis ATCC 29212. 
Results
Clinical Manifestation and serotype
A total of 105/198 neonates with GBS sepsis and/or meningitis included in the study 
were male (53%). Additional information was obtained from 108 neonates, of these 26% 
(28/108) were preterm (< 37 weeks) and the case-fatality rate was 7% (8/108). The GBS 
strain serotype Ia was isolated in 4 of the 8 patients who died.
A total of 184/198 (93%) strains could be serotyped. Serotypes Ia (37 (19%)) and III (109 
(55%)) predominated and serotypes VII and VIII were not found at all. The relationship 
between serotype and clinical manifestation of the disease is presented in table 1. 
Serotypes Ia and III were predominant with early-onset sepsis (12% (24/198) and 23% 
(46/198) respectively). Serotype III was predominant with late-onset sepsis and/or 
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meningitis (21% 41/198)). Meningitis was more frequent in late onset disease than in 
early-onset disease (respectively 61% (34/56) and 20% (29/142)). 
There was no difference in the serotype distribution between the two periods (1997-1998 
and 1999).
Table 1. Clinic manifestation and serotypes of 198 GBS strains from neonates with GBS sepsis and/or meningitis in 1997-1999 
in the Netherlands 
Clinic Total 
number
Serotypes
N % Ia Ib II III IV V VI Non-
typable
Early-onset
(≤7 days)
142 72 % % % % % % % %
Sepsis 113 57 24 12 5 2.5 15 7.5 46 23 - - 12 6 1 0.5 10 5
Meningitis 5 3 2 1 - - - - 2 1 - - 1 0.5 - - - -
Sepsis + 
Meningitis
24 12 4 2 - - - - 20 10 - - - - - - - -
Late-onset 
(> 7 days)
56 28
Sepsis 22 11 3 2 1 0.5 1 0.5 14 7 - - - - 3 1.5
Meningitis 10 5 2 1 - - - - 5 2.5 1 0.5 1 0.5 - - 1 0.5
Sepsis + 
Meningitis
24 12 2 1 - - - - 22 11 - - - - - - - -
Totaal 198 100 37 19 6 3 16 8 109 55 1 0.5 14 7 1 0.5 14 7
Genotyping
The GBS strains were genetically heterogeous, 198 different PFGE patterns were found 
(fi gure 1) and there was no difference found between the two periods. 
Susceptibility testing
MIC ranges and the MIC90 values are shown in table 2. Distributions of MIC’s are given 
in fi gure 2. All MIC distributions were unimodal. MIC90 for penicillin, amoxicillin, and 
cefi xime were 0.03 mg/l and for cefepime and meropenem were ≤ 0.03 mg/l, compared 
to 0.25 for ceftazidime. The MIC distribution of ceftazidime had a broad range (0.06-0.5 
mg/l). MIC 90 of erythromycin and clarithromycin were comparable; MIC90 of teicoplanin 
and quinupristin/dalfopristin was 0.12 mg/l, and for vancomycin four times higher (0.5 
mg/l). The MIC distribution curves of trovafl oxacin and moxifl oxacin were comparable 
with MIC90 at 0.25 mg/l; the MIC90 of ciprofl oxacin was four times higher (1mg/l). MIC’s 
ranged from 0.06-0.5 mg/l for trovafl oxacin and moxifl oxacin, and from 0.25-1.0 mg/l for 
ciprofl oxacin. 
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Table 2. MIC ranges and MIC90 of GBS strains
Antibiotic Concentration (mg/l)
Range MIC90
Penicillin 0.03-0.06 0.03
Amoxicillin 0.03-0.06 0.03
Ceftazidim 0.06-0.5 0.25
Ceﬁ xime 0.03-0.12 0.03
Cefepime 0.03-0.06 ≤ 0.03
Meropenem 0.03 ≤ 0.03
Erythromycin 0.03-128 0.06
Clarithromycin 0.03-128 0.03
Vancomycin 0.25-1.0 0.50
Teicoplanin 0.03-0.12 0.12
Quinupristin/dalfopristin 0.03-1.0 0.12
Ciproﬂ oxacin 0.25-1.0 1.00
Trovaﬂ oxacin 0.06-0.5 0.25
Moxiﬂ oxacin 0.06-0.25 0.25
Figure 1 PFGE patterns of GBS strains
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Discussion
In the Netherlands the serotype distribution of GBS strains did not change in the fi rst year 
(1999) after the introduction of antibiotic prophylaxis. May be a period of one year is too 
short to fi nd changes and therefore we compared our serotype distribution in 1998-1999 
with the serotype distribution that was found in a study on GBS epidemiology in the 
Netherlands in 1980.5 Like in 1980 serotype III was found frequently in 1997-1999. In 1980 
serotype Ib predominated and in 1997-1999 serotype Ia was more frequently found. A 
possible explanation for this difference is that the serotyping was performed in a different 
group of neonates. In 1980 the serotyping was performed in healthy neonates of mothers 
who were GBS carriers and in 1997-1999 in neonates with early-onset GBS sepsis and 
meningitis. Serotype Ia and III were predominant in patients with early-onset GBS sepsis 
and serotype III in patients with late-onset GBS sepsis and/or meningitis. This association 
of serotypes with the type of clinical disease was found by others as well.6,7 
The GBS strains were genetically heterogeous, confi rming the fi ndings in a previuos 
study in which we observed that all strains from 10 mothers-GBS carriers were genetically 
different. The strains from each mother and her own child were identical8. Hansen et al.9 
found the same results in GBS carriers.
We could not demonstrate any shift in susceptibility after the introduction of penicillin 
or amoxicillin prophylaxis for prevention of neonatal GBS disease. Since all strains were 
highly susceptible to all beta-lactams tested all of them may be effective for treatment of 
GBS septicaemia. However, not all beta-lactams showed equal pharmacodynamics: the 
Figure 2. Susceptibility testing: the distribution of MIC’s
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concentrations of ceftazidime and meropenem are not continuously maintained above 
the 10*MIC using the standard dosing schedules. To our opinion penicillin remain to be 
preferred over cephalosporins and meropenem for treatment of GBS sepsis as stated by 
others as well.10,11
Teicoplanin appeared to be the most active glycopeptide. This antibiotic drug is not 
the glycopeptide of fi rst choice in most neonatal units, but because of its activity and 
the dosing of once daily it might be considered as an alternative for septicaemia when 
beta-lactams are contraindicated. Experience with quinupristin and dalfopristin in the 
treatment of neonatal disease is very limited. The same holds true for the macrolides. 
Erythromycin and clarithromycin showed equal antimicrobial activity, but the experience 
with macrolides for treatment of GBS disease is limited. 
In conclusion, one year after the introduction of antibiotic prophylaxis of neonatal 
GBS disease in the Netherlands the serotype distribution and the genotype and the 
susceptibility patterns of the GBS strains did not change so far and penicillins remain 
drugs of fi rst choice for prevention and treatment of neonatal GBS disease.
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General Discussion
The development of guidelines for prevention of early-onset GBS disease in the Netherlands
Since the 1970’s group B Streptococcus (GBS) has been recognised as the leading cause 
of severe neonatal early-onset infection. The majority of neonatal early onset GBS 
infection can be prevented by intrapartum antibiotic prophylaxis in women who are 
at increased risk for transmitting the infection to their newborn. In the early 90’s the 
incidence of proven early-onset GBS sepsis in the USA was high and varied between 
1.1 and 3.7 per 1000 live births. 1 Therefore, in 1996 the CDC recommended nationwide 
guidelines for prevention of early-onset GBS sepsis, that were approved by the American 
Academy of Pediatrics and the American College of Obstetricians and Gynecologists. 
In these nationwide guidelines the use of one of two prevention strategies was 
recommended. In the fi rst, screening-based strategy, intrapartum antibiotic prophylaxis 
is offered to women identifi ed as GBS carriers by cultures collected at 35-37 weeks 
gestation from the vagina and rectum. When these cultures are not performed or the 
result is unknown, antibiotic prophylaxis is offered to women with the following risk-
factors at the time of labour: premature onset of labour (<37 weeks), prolonged rupture 
of membranes (>18h), intrapartum fever (>38°C), GBS bacteriuria during the current 
pregnancy and previous delivery of an infant with invasive GBS disease. In the second, 
risk factor-based strategy, intrapartum antibiotic prophylaxis is offered to all women with 
one or more of the risk factors mentioned by the screening-based strategy. 2 After the 
introduction of these prevention strategies the incidence of proven early-onset sepsis in 
selected areas of the USA decreased from 1.7 per 1000 live births in 1993 to 0.6 per 1000 
live births in 1998. 3 
In 1998, the Dutch Paediatric Association and the Dutch Society of Obstetrics and 
Gynaecology developed guidelines for prevention of early-onset GBS disease. 
In chapter 2 a general introduction is given of the development of these guidelines, 
which were based on the presence of fi ve risk factors, similar to one of the two 
recommended strategies in the USA in 1996. Intrapartum chemoprophylaxis is 
recommended in case of previous delivery of an infant with serious GBS disease or GBS 
bacteriuria during the current pregnancy. In case of intrapartum maternal fever (> 38°C) 
broad-spectrum antibiotics are administered. To reduce the number of women that 
would receive antibiotic prophylaxis during delivery, it was recommended that in case 
of premature onset of labour before 37 weeks and/or prolonged rupture of membranes 
(>18-24h) screening for GBS carriership is performed fi rst, followed by antibiotic 
prophylaxis after the culture became positive. When the delivery occurs before the result 
of the culture is available, the obstetrician should decide about antibiotic prophylaxis, 
based on the severity of the risk factor(s). The choice for this risk factor-based strategy 
was based on currently available knowledge and the specifi c Dutch situation, with 
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approximately 30% home deliveries. In general midwives and general practitioners 
are monitoring these pregnancies. All women with at least one of the fi ve risk factors 
described before will always be referred to a hospital. Therefore the risk based strategy 
would not interfere with regular practice. Furthermore this risk factor based-strategy was 
implemented before the defi nitive results of the study of the nationwide incidence of the 
disease were available. It was estimated that the total incidence of proven and probable 
sepsis was relatively low (0.9 per 1000 live births), compared with the incidence in the 
USA before the introduction of guidelines.
Incidence of neonatal GBS disease and prevention strategies in Europe 
In chapter 3, we describe the results of a survey of GBS disease in Europe. From 
questionnaires sent in December 1999 to all members of the European Society for 
Paediatric Infectious Disease and to all national delegates of the European Association 
of Perinatal Medicine we collected data concerning maternal GBS colonisation and 
the incidence of neonatal GBS disease in the different countries. Of the 33 European 
countries involved, 29 were represented by at least one respondent. We found that the 
incidence of GBS colonisation during pregnancy in Europe varied from 1.5- 30 % and 
that the incidence of neonatal GBS disease varied from 0.2-4 per 1000 live births. The 
differences could, at least partly, be explained by the use of different data collection 
sources (regional, national), differences in defi nition of GBS sepsis (probable and/or 
proven cases) and differences in the culture methods. Furthermore we found that 
nationwide guidelines for prevention of neonatal GBS infection were available at that 
time in only 4 of 29 European countries: Denmark, Norway, Spain and the Netherlands. 
About one-half of the respondents reported the existence of local hospital-based 
protocols in their institutions, but the prevention practices varied among doctors and 
institutions. Our conclusion of this study was that because of the lack of epidemiological 
data and uniform methods, a surveillance study in European countries would be needed 
for determination of the most appropriate prevention policy for early-onset GBS sepsis.
The epidemiology of neonatal GBS disease before and after the introduction of the Dutch guidelines for prevention 
of early-onset GBS disease
Nationwide epidemiological data on neonatal GBS disease in the Netherlands were 
not available before 1997. In chapter 4, we studied the epidemiology of GBS disease 
during the fi rst three months of life, based on all infants with the disease as reported to 
the Dutch Paediatric Surveillance Unit (DPSU) during a period of 2 years (1997-1998) 
before the introduction of nationwide guidelines in 1999. Neonates with early-onset 
GBS disease (proven and probable sepsis) were included for analysis. Proven sepsis 
was defi ned by the simultaneous presence of clinical features of septicaemia, abnormal 
results of laboratory investigations as well as a positive culture of blood and/or 
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cerebrospinal fl uid. Probable sepsis was defi ned by the presence of the same clinical 
and laboratory features and the isolation of GBS from various sites, but without positive 
blood or CSF culture. The level of completeness of the DPSU data was determined by 
capture-recapture techniques. The overall incidence of early-onset GBS disease (sepsis 
and probable sepsis) in 1997-1998, as calculated from the DPSU data, was 0.9 per 1000 
live births. After correction for under-reporting, the incidence was estimated to be 1.9 
per 1000 live births. The corrected incidence of proven early-onset GBS sepsis alone 
was 0.6 per 1000 live births. This was lower than we had expected and also much lower 
than the incidence of proven early-onset sepsis that was found in the USA before the 
introduction of prevention guidelines (1.1-3.7 per 1000 live births). 1 Despite the decrease 
in the case fatality rate of early-onset GBS disease during the last decades from about 
30% to 5% found in this study, it remains a serious condition and survivors may suffer 
permanent disability (e.g., hearing or visual loss or mental retardation). In chapter 5, 
we studied the epidemiology of neonatal GBS disease over fi ve years (1997-2001) in the 
Netherlands stratifi ed for proven and probable sepsis. We evaluated the introduction 
of the guidelines for prevention of early-onset GBS disease, in a period of three years 
(1999-2001) after and compared it with a period of two years (1997-1998) before the 
introduction of the guidelines in 1999. As in 1997-98 cases were collected in co-operation 
with the DPSU and corrected for under-reporting by the capture-recapture technique. 
We found that the incidence of proven and probable neonatal GBS sepsis during the 
whole period (1997-2001) in the Netherlands was 0.56 per 1000 live births and 1.38 per 
1000 live births respectively. Early-onset disease usually is defi ned by the occurrence of 
the fi rst symptoms in the fi rst seven days after birth. We subcategorised early-onset GBS 
sepsis in “very early-onset” (<12 h) and “late early-onset” (12 h-< 7d) and found that in 
76% of the proven early-onset cases the fi rst symptoms occurred within 12 hours after 
birth. In these patients, the risk factors prolonged rupture of membranes and intrapartum 
fever were present more frequently and the mothers of these patients were more 
frequently primigravid. In none of the patients with late early-onset disease the risk factor 
intrapartum fever was present. Because of these reasons, we consider it appropriate to 
distinguish very early-onset (<12 h) from early-onset disease. The overall effect of the 
Dutch guidelines is disappointing, because the incidence of proven neonatal early-onset 
GBS sepsis decreased from 0.54 per 1.000 live births in 1997-1998 to 0.36 per 1000 live 
births in 1999-2001 (RR 0.67 (min-max: 0.48-0.98) and the incidence of probable sepsis, 
late-onset sepsis, meningitis and mortality did not decrease. An alternative for prevention 
of both neonatal early-onset and late-onset GBS disease is vaccination. Some studies 
indicate that a GBS conjugate vaccine given in a single dose around 26 weeks gestation, 
would be expected to be safe and highly effective and would, prevent about 90% of both 
early-onset and late-onset GBS infections. 4 
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The Dutch guidelines are based on recognition of risk factors and in order to limit 
antibiotic prophylaxis during delivery, screening is performed fi rst in case of labour 
before 37 weeks and/or prolonged rupture of membranes, followed by antibiotic 
prophylaxis in case of a positive culture. Therefore the Dutch guidelines can be expected 
to have limited effectiveness since in case of preterm labour and/or prolonged rupture 
of membranes cases can be missed because of the delay of obtaining culture results. 
Moreover, during the study period no adequate rapid intrapartum test was available and 
in 46% of the proven early-onset cases risk factors were absent. It was shown in the USA 
that for these reasons the screening-based strategy is more effective than the risk-factor 
based strategy and in 2002 the CDC published a report with revised guidelines, in which 
only one strategy, the screening- based strategy, was recommended. 5,6 Because the 
effectiveness of the Dutch risk factor based guidelines for prevention of neonatal GBS 
disease is limited, we recommend adaptation of these guidelines to cover more cases in 
which risk factors are absent.
The compliance to the Dutch guidelines to prevent neonatal Group B Streptococcal disease
In chapter 6 we evaluated the implementation of the Dutch risk factor based guideline 
for prevention of early-onset GBS disease by gynaecologists. To be able to evaluate 
whether a change in incidence in early-onset GBS-sepsis results from the implementation 
of the guidelines, we performed a survey about attitudes and policies related to the use 
of antibiotics for prevention of GBS disease two years before (1997) and one year after 
(2000) the introduction of the nationwide prevention guidelines in 1999. 
In 1997 and 2000 we sent a questionnaire to a random sample of 120 gynaecologists and 
we took a stratifi ed sample of 10% of all hospitals providing perinatal care for an in-depth 
study of actual obstetrical practice, based on the medical records. In 1997, 89% (71/80) 
of the gynaecologists reported that a local protocol for administration of intrapartum 
antibiotics was available. In 2000, all gynaecologists were familiar with the Dutch GBS 
prevention guidelines and 91% (62/68) reported that there was consensus in their 
hospital to use it. Overall, the total percentage of administration of intrapartum antibiotics 
increased from 1% in 1997 to 5.9% in 2000. However we would expect that after 
implementation of the guidelines antibiotic prophylaxis would be given in about 10-15% 
of all deliveries. The antibiotic drug that was used most often was amoxicillin/clavulanic 
acid. In none of the pregnancies in which antibiotic prophylaxis was indicated penicillin, 
the antibiotic drug of fi rst choice in the guidelines was adequately used. Overall, the 
compliance to the Dutch risk factor based guidelines to prevent neonatal Group B 
Streptococcal disease was disappointing. 
In order to increase the compliance to the Dutch guidelines, the fi rst possibility would be 
to place greater emphasis on the information to gynaecologists, midwives, paediatricians, 
as well as parents. Another possibility is changing our Dutch risk factor based guidelines. 
90 Chapter 8
The guidelines can be expected to have limited effectiveness since in case of preterm 
delivery and/or prolonged rupture of membranes cases can be missed because of the 
delay of obtaining culture results.
Another reason for limited effectiveness is the fact that in about 40-50% of all cases of 
early-onset GBS sepsis no maternal risk factor is present. It was shown in the USA in 2002 
that the screening based strategy is more effective than the risk factor based strategy..5 
The choice for either risk factor or screening based strategy should be cost-effective as 
well. In a recent study a cost-effectiveness analysis based on different decision models 
for the Dutch situation was performed that showed that the risk based strategy (as 
recommended by the CDC in 1996) and a combined screening/risk-based strategy are 
reasonable cost-effective. 7 
It is concluded that the implementation of the Dutch risk factor based guidelines resulted 
in an increase of intrapartum antibiotic use, but there still is a poor compliance to the 
guidelines 
The distribution of the diﬀ erent GBS serotypes, genotypes and changes in antibiotic susceptibility before and after 
the introduction of the guidelines for prevention 
In Chapter 7 we studied the characteristics of strains isolated from neonates with GBS 
sepsis and meningitis in two periods, before (1997-1998) and after (1999) the introduction 
of antibiotic prophylaxis in the Netherlands. Serotyping, genotyping and susceptibility 
testing of 198 GBS strains obtained from blood and/or cerebrospinal fl uid was performed. 
There was no difference in the serotype distribution of GBS strains between the two 
periods, but a period of one year probably is too short to fi nd changes. Serotype Ia and 
III were predominant in patients with early-onset GBS sepsis and serotype III in patients 
with late-onset GBS sepsis and/or meningitis. Others found this association of serotypes 
with the type of clinical disease as well. 8 The 198 GBS-strains isolated were genetically 
all different and the clinical presentation of neonatal GBS disease was not associated 
with any of the genotypes. These fi ndings confi rmed a previous study in which we 
observed that the strains from 10 GBS carriers were all genetically different, but that the 
strains from each mother-child pair were identical. 9 There was no shift in susceptibility 
of the GBS-strains after the introduction of the guidelines for antibiotic prophylaxis and 
penicillin remains the drug of choice for both prophylaxis and treatment of neonatal GBS 
disease.
General Discussion 91
Future Perspectives 
Adaptation of the guidelines for early-onset GBS disease in the Netherlands
The overall effect of the Dutch risk factor based guidelines is disappointing; since there 
was only a moderate decrease of the incidence of proven neonatal early-onset GBS 
sepsis whereas the incidence of case fatality rate, meningitis and probable sepsis did 
not decrease. Furthermore we found that the implementation of the Dutch guidelines 
resulted in an increase of intrapartum antibiotics use, but there is a large gap between the 
presumed and the actual compliance to the guidelines by the gynaecologists. Therefore 
we recommend an adaptation of the Dutch guidelines to cover more cases of GBS 
disease in which risk factors are absent. The choice for an adapted prevention strategy in 
the Netherlands should be based on current scientifi c knowledge and cost-effectiveness. 
The fi rst possibility is to change the guidelines in risk factor based guidelines as recom-
mended in 1996 by the CDC. 2 In these guidelines intrapartum antibiotic prophylaxis is 
offered to all women with one or more of the following risk factors: premature onset 
of labour (<37 weeks), prolonged rupture of membranes (>18h), intrapartum fever 
(>38°C), GBS bacteriuria during the current pregnancy and previous delivery of an infant 
with invasive GBS disease. By using these guidelines the effectiveness should be better, 
because in case of preterm delivery and/or prolonged rupture of membranes cases could 
not be missed any more, because there is no delay to obtain the culture results. 
The second possibility is to change the guideline in combined screening- and risk-based 
guidelines. In these guidelines screening for GBS carriership is performed at 35-37 weeks 
gestation, when the GBS culture is positive and the pregnant woman had one or more of 
the risk factors mentioned above for the risk-based strategy, antibiotic prophylaxis will be 
offered.
However, the risk factor based guidelines and combined screening-and risk-based 
guidelines still have a limited effectiveness because in about 40-50% of all cases of early-
onset GBS sepsis no maternal risk factor is present at all, so these cases will be missed.
Therefore the third possibility is changing the guidelines in screening based guidelines 
as recommended by the CDC in 2002. 6 In these guidelines intrapartum antibiotic 
prophylaxis is offered to women identifi ed as GBS carriers by cultures collected at 35-37 
weeks gestation from the vagina and rectum. When these cultures are not performed 
or the result is (still) unknown, antibiotic prophylaxis is offered to women with the risk 
factors mentioned for the risk factor based strategy. The CDC based this recommendation 
on a comparative study of the risk factor based and screening-based strategy from which 
it was concluded that the screening-based strategy was over 50% more effective than the 
risk-based strategy. 5 However, the screening based guidelines have some adverse effects 
that should be taken into consideration. First of all, it would necessitate changing the 
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organisation of Dutch perinatal care, since approximately 30% of all deliveries take place 
at home under the guidance of midwives and general practitioners. These circumstances 
are not ideal for screening based guidelines. Another adverse effect is the use of antibiotic 
prophylaxis in a substantial number of pregnant women, since in the Netherlands 
GBS carriership during pregnancy is about 15-20%. This would increase the risk of 
development of antibiotic resistance that has been reported already to erythromycin 
and clindamycin, and the selection of resistant gram-negative organism, especially when 
broad spectrum antibiotics are used. 10-13 Also the increase of potentially severe adverse 
reactions including anaphylaxis to penicillin, which occurs in about 0.01%, could become 
a problem. 14 
Because of these adverse effects, another possibility would be to move to a strategy 
of vaginal disinfection with chlorhexidine during labour for preventing GBS early-
onset infection in neonates. 15 Chlorhexidine has no impact on antibiotic resistance, is 
inexpensive and could be used at home. In 2004 a systematic review was published 
in which fi ve studies (including 2190, both term and preterm infants) were analysed. 
The conclusion was that vaginal disinfection with chlorhexidine during labour resulted 
in a statistically signifi cant reduction in GBS colonisation of neonates, but the studies 
were not large enough to draw conclusions regarding reduction of GBS-infections. 16 In 
the Netherlands a randomised trial is planned to study the cost-effectiveness of vaginal 
chlorhexidine fl ushing compared to intravenous antibiotics during term delivery to 
prevent vertical transmission of group B streptococcus. 
Important for the selection of the best prevention strategy is the cost-effectiveness. In 
the Netherlands van den Akker et al. 7 performed a cost-effectiveness analysis based on a 
decision model, to estimate the costs and effects of four of the fi ve different prevention 
strategies we mentioned before : 1. a risk-based strategy, 2. combined screening- and 
risk-based strategy 3. a screening-based strategy and 4. the current Dutch risk-based 
strategy. They found that in the Dutch system the combined screening- and risk-based 
strategy and the risk-based strategy both have reasonable cost-effectiveness ratios. The 
screening-based strategy was less cost-effective. This higher amount of estimated costs of 
the screening based strategy could partly be explained by the costs of 48 hours clinical 
observation of healthy infants of GBS culture positive mothers.The costs of this neonatal 
observation period contribute to more than half of the total costs in the screening 
approach estimated by van den Akker et al. Although 48-hours clinical observation was 
recommended in our current Dutch guidelines (and the CDC guidelines), the necessity 
for this procedure in the Netherlands may be questioned. In the Netherlands an effective 
postnatal home care system exists supervised by midwives and specially trained maternity 
nurses, which could well replace the need for clinical observation. Omitting the clinical 
observation of clinically healthy infants reduces the costs calculated for the screening 
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based strategy considerably. Therefore, we believe the screening-based strategy could 
have reasonable health care costs. 
Also important for the selection of the best prevention strategy is the incidence of proven 
early-onset GBS sepsis. The (corrected) incidence of proven early-onset GBS sepsis alone 
was 0.6 per 1000 live births in 1997-1998, which was lower than we had expected and 
it was also much lower than the incidence of proven early-onset sepsis that was found 
in the USA before the introduction of the prevention guidelines (1.1-3.7 per 1000 live 
births ). 1 According to our study, the incidence of proven early-onset GBS sepsis in the 
Netherlands decreased to 0.36 per 1000 live births after the introduction of the current 
Dutch guidelines. With this low incidence no prevention strategy can have reasonable 
cost-effectiveness ratios because it was found that any prevention guideline could be 
cost-effective when the incidence of early-onset GBS sepsis is > 0.6 per 1000 live births. 14 
In the future, vaccination against GBS is possible the most effective strategy, preventing 
about 90% of both early-onset and late-onset GBS infections. It would prevent about 
twice as many cases of death and disability in the neonate as the screening-based strategy 
and three times as many as the risk factor based strategy. Unfortunately, a fully effective 
vaccine, inducing antibodies against all fi ve GBS serotypes (Ia, Ib, II, III and V) that may 
cause the disease is not available yet. 17 
 
In conclusion: Although screening based guidelines are the most cost-effective approach 
to prevent early-onset GBS infection in the USA, these guidelines carry a number of 
disadvantages and in the Netherlands the incidence of proven early-onset GBS sepsis is 
low. 
Therefore in the Netherlands a decision could not be made until now. Currently 
discussions on how to adapt the Dutch risk factor based guidelines are ongoing.
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Summary
Since the 1970’s group B Streptococci (GBS) remain an important cause of severe 
neonatal early-onset infection, despite the fact that in the last 25 years the case fatality 
rate of neonatal early-onset GBS sepsis has decreased from about 55% to 5-10%. Neonatal 
early-onset GBS infection can be prevented by intrapartum antibiotic prophylaxis in 
women who are at increased risk for transmitting the infection to their newborn. The 
Center for disease Control and Prevention (CDC, USA) recommended in 1996 prevention 
guidelines based on either one of two strategies. The fi rst strategy was based on universal 
screening for GBS colonization and the second strategy was based on the presence 
of risk factors. In 1999, the Dutch Society of Obstetrics and Gynaecology (NVOG) 
and the Paediatric Association of the Netherlands (NVK) issued guidelines based on 
risk factors (Chapter 2). The choice for a risk based strategy is based on an estimated 
relatively low total incidence of proven (blood culture positive) and probable (blood 
culture negative, despite clinical and laboratory signs of sepsis) GBS sepsis of 0.9 per 
1000 live births in the Netherlands, compared with the incidence in the USA before the 
introduction of guidelines (1.1-3.7 per 1000 live births). Furthermore the choice is based 
on the organization of Dutch perinatal care, with approximately 30% home deliveries. 
In general these pregnancies are monitored by midwives and general practitioners who 
should, according to the referral protocol for midwifes, refer women with one of the 
risk factors, as described in the guidelines, to a hospital. The Dutch risk factor based 
guidelines are as follows. Chemoprophylaxis is recommended in case of a previous infant 
with GBS disease and in heavily colonised mothers. In case of intrapartum fever (>38.0 
ºC) antibiotics must be administered. In order to limit the number of women that would 
receive chemoprophylaxis, it was recommended that in case of labour before 37 weeks 
or prolonged rupture of membranes (≥ 18 –24 hours), screening for GBS carriership is 
performed fi rst, followed by chemoprophylaxis when the culture becomes positive. In 
case of delivery before the culture result is available, the obstetrician is allowed to decide 
about prophylaxis. Therefore the Dutch guidelines can be expected to have a limited 
effectiveness since in case of preterm labour and/or prolonged rupture of membranes 
cases can be missed because of the delay of obtaining culture results and during the 
study period no adequate rapid intrapartum test was available. 
In a survey of GBS disease in Europe (Chapter 3) we found that the incidence of GBS 
colonization during pregnancy and the incidence of neonatal GBS disease varied widely, 
respectively from 1.5-30% and from 0.2-4 per 1000 live births. Furthermore, at that time 
in only 4 of 29 European countries (Denmark, Norway, Spain and the Netherlands) 
nationwide guidelines for prevention of neonatal GBS infection were available.
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In chapters 4 and 5 the results of our study of the epidemiology of neonatal GBS disease 
is described, in a period of two years before (1997-1998) compared to a period of three 
years (1999-2001) after the introduction of the Dutch guidelines in 1999. The overall effect 
of the introduction of these guidelines is disappointing, because only the incidence of 
proven neonatal early-onset GBS sepsis decreased from 0.54 (in 1997-1998) to 0.36 (in 
1999-2001) per 1000 live births and the incidence of probable GBS sepsis, meningitis 
and case fatality rate did not decrease. With the introduction of the Dutch guidelines 
33% of cases with early-onset GBS sepsis were prevented instead of 69% that would be 
prevented with the risk factor based strategy, as recommended by the CDC in 1996.
To be able to evaluate whether the decrease of the incidence in proven early-onset GBS 
sepsis resulted from the implementation of the guidelines by the Dutch gynaecologists, 
we performed a survey on the availability of GBS prevention protocols as well as the 
adherence to them both in 1997 (two years before) and in 2000 (one year after) the 
introduction of the guidelines (chapter 6). In 2000, all gynaecologists were familiar with 
the Dutch guidelines and 91% (62/68) reported that there was consensus in their hospital 
to use it. Overall, intrapartum antibiotic administration increased from 1% in 1997 to 5.9% 
in 2000. However, we would have expected that after implementation of the guidelines 
intrapartum antibiotic prophylaxis be given in about 10-15% of all deliveries. In none of 
the pregnancies in which antibiotic prophylaxis was indicated penicillin, the antibiotic 
drug of fi rst choice in the guidelines was adequately used. The antibiotic drug used most 
often was amoxicillin/clavulanic acid. This could increase the risk of development of 
antibiotic resistance and selection of resistant Gram-negative organism. We concluded that 
there still is a large gap between the ‘physicians’ owns presumed and actual compliance 
to the guidelines.
In chapter 7 we studied the characteristics of strains isolated from neonates with GBS 
sepsis and meningitis before (1997-1998) and after (1999) the introduction of Dutch 
guidelines for prevention of early-onset GBS disease. There was no change in serotyping 
and genotyping and no shift in susceptibility of the GBS-strains. Penicillin remains the 
drug of choice for both prophylaxis and treatment of neonatal GBS disease.
Implementation of the Dutch risk factor based guidelines was poor and the overall 
effect is moderate, since only the incidence of proven neonatal early-onset GBS sepsis 
decreased to some extent. Despite the increase of intrapartum antibiotic administration, 
there is a clear discrepancy between the gynaecologists presumed and actual compliance 
with the guidelines.
Therefore we recommend an adaptation of the Dutch guidelines. Adaptation of the 
guidelines to more strict risk factor based guidelines as recommended by the CDC 
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(1996) as well as to a combined screening- and risk-based strategy would still have 
limited effectiveness because in about 40-50% of all cases of early-onset GBS sepsis no 
maternal risk factor is present, and these cases would be missed. Another possibility 
would be to move to screening-based guidelines as recommended as the only strategy 
by the CDC (2002), because this strategy is over 50% more effective than the risk-based 
strategy. However these guidelines have some disadvantages: 1. Universal screening 
would be complex because of the large percentage of home deliveries, 2. Increased use 
of intrapartum antibiotic prophylaxis has increased risk of development of antibiotic 
resistance and selection of resistant gram-negative organism, as well as increase of 
adverse reactions including anaphylaxis to penicillin. Still another possibility would be 
a strategy with vaginal disinfection with chlorhexidine during labour. Chlorhexidine has 
no impact on antibiotic resistance, is inexpensive and could be used at home. From a 
systematic review it was concluded that vaginal disinfection with chlorhexidine during 
labour results in a statistically signifi cant reduction in GBS colonization of neonates, but 
the studies performed so far were not large enough to draw conclusions with respect to 
reduction of GBS infections.
In the future, vaccination against GBS might become the most effective strategy in 
preventing both early-onset and late-onset GBS infection. Unfortunately, an effective 
vaccine is not available yet.
Cost-effectiveness and the incidence of proven early-onset GBS-sepsis are also important 
for the selection of the best prevention strategy in the Netherlands. This incidence was 
0.6 per 1000 live births, much lower than we had expected and much lower than the 
incidence of proven early-onset GBS sepsis in the USA, before the introduction of the 
CDC prevention guidelines. With this low incidence, no prevention strategy could have 
reasonable cost-effectiveness ratios. 
In conclusion: 
We evaluated the nationwide Dutch risk factor based guidelines for the prevention 
of neonatal early-onset GBS disease, issued in 1999, in order to facilitate further 
improvement of these guidelines. In Europe the incidence of GBS colonisation during 
pregnancy and the incidence of neonatal GBS disease vary widely. In only four European 
countries nationwide prevention guidelines were available in 1999. After the introduction 
of the Dutch guidelines in 1999, there was a moderate decrease of the incidence of 
proven neonatal early-onset GBS sepsis. Although most gynaecologists were familiar with 
these guidelines and have consensus about them, the actual implementation was low. 
There was no change in serotyping and genotyping and no shift in susceptibility of the 
GBS-strains before (1997-1998) and after (1999) the introduction of the guidelines. 
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The overall effect of the introduction of the Dutch risk based guidelines is disappointing 
and therefore there is an ongoing discussion on how to develop the most effective 
prevention guidelines for the specifi c Dutch situation. 
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Samenvatting
Sinds de jaren zeventig vormen Groep B Streptokokken (GBS) een belangrijke oorzaak 
voor ernstige neonatale early-onset infecties, hoewel de sterftekans hierbij gedurende 
de afgelopen 25 jaar is gedaald van ongeveer 55% tot 5-10%. Neonatale early-onset 
GBS besmetting kan worden voorkomen door antibiotische profylaxe te geven tijdens 
de bevalling aan vrouwen die een verhoogd risico hebben om de infectie op hun 
pasgeboren kind over te dragen. In 1996 vaardigde het Center for Disease Control and 
Prevention (CDC, VS) preventieve richtlijnen uit, gebaseerd op twee strategieën. De 
ene strategie ging uit van algemene screening voor GBS dragerschap, terwijl de andere 
strategie was gebaseerd op de aanwezigheid van risicofactoren. In 1999 brachten de 
Nederlandse Vereniging voor Obstetrie en Gynaecologie (NVOG) en de Nederlandse 
Vereniging voor Kindergeneeskunde (NVK) richtlijnen uit die eveneens gebaseerd waren 
op risicofactoren (hoofdstuk 2). De keuze voor een methode op basis van risicofactoren 
werd ingegeven door een geschatte relatief lage incidentie van bewezen (positieve 
bloedkweek) en waarschijnlijke (negatieve bloedkweek ondanks klinische symptomen 
en afwijkende laboratoriumwaarden in het bloed) GBS sepsis van 0.9 per 1.000 levend 
geborenen in Nederland, vergeleken met de incidentie in de VS vóór de introductie van 
de richtlijnen (1.1-3.7 per 1.000 levend geborenen). Bovendien werd de keuze gebaseerd 
op de wijze waarop de verloskundige zorg in Nederland is georganiseerd, met circa 
30% thuisbevallingen. Deze zwangerschappen worden begeleid door vroedvrouwen en 
huisartsen, die vanwege hun rol bij normaal verlopende zwangerschappen, vrouwen met 
een van de in de richtlijnen genoemde risicofactoren naar de gynaecoloog verwijzen. De 
Nederlandse, op risicofactoren gebaseerde, richtlijnen luiden als volgt. 
Antibiotische profylaxe wordt aanbevolen in geval van een eerder kind met GBS ziekte of 
van een ernstig gekoloniseerde moeder (dit houdt in dat moeder tijdens de zwangerschap 
een positieve urinekweek voor GBS heeft gehad). In geval van koorts (> 38.0 C) tijdens 
de bevalling dienen antibiotica te worden toegediend. Om het aantal vrouwen dat 
antibiotische profylaxe ontvangt te beperken wordt aanbevolen om in geval van bevalling 
vóór 37 weken of langdurig gebroken vliezen (> 18-24 uur) eerst een screening voor 
GBS dragerschap uit te voeren. In geval van een positieve kweek van de vagina of de 
baarmoedermond vindt daarna alsnog antibiotische profylaxe plaats. Indien de bevalling 
plaatsvindt vóórdat de uitslag van de kweek beschikbaar is, is het aan de gynaecoloog 
om wel of niet te kiezen voor profylaxe. 
Van de Nederlandse richtlijnen mag daarom slechts een beperkte effectiviteit worden 
verwacht, aangezien in geval van vroege bevalling en/of langdurig gebroken vliezen 
gevallen kunnen worden gemist als gevolg van vertraging in de beschikbaarheid van 
kweekuitslagen.
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In een onderzoek naar GBS ziekte in Europa in 1999 (hoofdstuk 3) vonden we dat de 
incidentie van GBS kolonisatie tijdens de zwangerschap en de incidentie van neonatale 
GBS ziekte sterk uiteenliepen, respectievelijk van 1.5 tot 30% en van 0.2 tot 4 per 1.000 
levendgeborenen. Voorts waren op dat moment in slechts 4 van 29 Europese landen 
(Denemarken, Noorwegen, Spanje en Nederland) nationale richtlijnen voor de preventie 
van neonatale GBS infectie beschikbaar.
In hoofdstuk 4 en 5 beschrijven we de resultaten van ons onderzoek naar de 
epidemiologie van neonatale GBS ziekte, waarbij we een periode van twee jaar (1997-
1998) vóór invoering van de Nederlandse richtlijnen in 1999 vergeleken met de periode 
van drie jaar daarna (1999-2001). Over het geheel genomen is het effect van de invoering 
van deze richtlijnen teleurstellend, aangezien slechts de incidentie van bewezen neonatale 
early-onset GBS sepsis daalde van 0.54 (in 1997-1998) tot 0.36 (in 1999-2001) per 1.000 
levend geborenen. De incidentie van waarschijnlijke GBS sepsis en/of meningitis en de 
sterftekans namen echter niet af. Na de invoering van de Nederlandse richtlijnen werden 
33% van de gevallen van early-onset GBS sepsis voorkomen, in plaats van de 69% die 
theoretisch zou kunnen worden voorkomen met de strikt op risicofactoren gebaseerde 
strategie zoals aanbevolen in de VS.
Om vast te kunnen stellen of de daling van de incidentie van bewezen early-onset 
GBS sepsis een gevolg was van de implementatie van de richtlijnen door de 
Nederlandse gynaecologen, hebben we, in 1997 en in 2000 onderzoek gedaan naar de 
beschikbaarheid van GBS preventieprotocollen evenals naar de mate waarin ze werden 
nageleefd (hoofdstuk 6). In 2000 gaven alle gynaecologen aan dat ze de Nederlandse 
richtlijnen kenden en 91% meldde dat er overeenstemming was over het gebruik hiervan 
in hun ziekenhuis. Uit onderzoek van de patiëntengegevens bleek dat over het geheel 
genomen het gebruik van antibiotica gedurende de bevalling steeg van 1% in 1997 naar 
5.9% in 2000. We hadden echter verwacht dat na de implementatie van de richtlijnen het 
antibioticagebruik gedurende de bevalling zou zijn toegenomen naar ongeveer 10 -15% 
van alle bevallingen. In de zwangerschappen waarbij antibiotische profylaxe geïndiceerd 
was, werd penicilline (het middel van eerste keuze in de richtlijnen) nimmer op een 
adequate wijze gebruikt. Amoxicilline/clavulaanzuur werd het meest gebruikt. Hierdoor 
kan er een stijging van het risico op antibioticaresistentie en selectie van gram negatieve 
bacteriën optreden. We concludeerden dat er een verschil is in wat dokters denken dat ze 
doen en wat ze daadwerkelijk in de praktijk doen.
In hoofdstuk 7 hebben wij onderzoek gedaan naar kenmerken van GBS -stammen 
die werden gekweekt bij pasgeborenen met een GBS sepsis en/of meningitis vóór 
(1997-1998) en na (1999) de introductie van de Nederlandse richtlijn voor preventie van 
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early-onset GBS ziekte. Er trad geen verandering op in serotypen en genotypen, noch 
vond er een wijziging plaats in gevoeligheid van de GBS stammen voor antibiotica. 
Penicilline blijft het middel van eerste keuze voor zowel profylaxe als behandeling van 
neonatale GBS ziekte.
Implementatie van de Nederlandse richtlijnen was matig en over het geheel genomen 
was er weinig effect, aangezien er alleen een geringe daling was van de incidentie van 
bewezen neonatale early-onset GBS sepsis. Hoewel er een stijging werd gezien van het 
antibioticagebruik gedurende de bevalling, is er een duidelijke discrepantie tussen hoe 
gynaecologen denken en aangeven dat er overeenstemming over de richtlijn is en hoe dit 
in de praktijk werkelijk is.
Om deze redenen adviseren wij een aanpassing van de huidige Nederlandse richtlijnen. 
Indien de op risicofactoren gebaseerde richtlijnen strikter zouden worden toegepast 
conform de aanbevelingen uit 1996 in de VS, of indien er over zou worden gegaan op 
een gecombineerde richtlijn, gebaseerd op algemene screening èn risicofactoren, dan 
zouden deze richtlijnen in beide gevallen eveneens een beperkte effectiviteit houden. 
Immers, bij 40-50% van alle patiënten met een bewezen early-onset GBS sepsis zijn geen 
risicofactoren aanwezig en deze patiënten worden dus gemist. Een andere mogelijkheid 
zou zijn om over te gaan op een richtlijn die alleen is gebaseerd op algemene screening, 
zoals in 2002 in de VS geadviseerd werd. Deze richtlijn is meer dan 50% effectiever 
dan de richtlijn die op risicofactoren is gebaseerd. Er zijn echter ook enkele nadelen: 1. 
Algemene screening zou in Nederland erg ingewikkeld zijn vanwege het hoge aantal 
thuisbevallingen; 2. Er kan een stijging van het risico op resistentieontwikkeling en 
selectie van gram negatieve bacteriën optreden; 3. Kans op een stijging van allergische 
reacties, inclusief anafylactische shock, voor penicilline. Er is nog een ander beleid 
mogelijk, namelijk vaginale spoeling met chloorhexidine bij de bevalling. Chloorhexidine 
leidt niet tot resistentie ontwikkeling, is goedkoop en kan ook bij een thuisbevalling 
worden toegepast. De conclusie uit een recent overzichtsartikel luidde dat vaginale 
desinfectie met chloorhexidine gedurende de bevalling resulteert in een signifi cante 
daling van GBS dragerschap bij pasgeborenen. De beschikbare studies zijn echter 
niet groot genoeg om conclusies te trekken voor wat betreft het aantal infecties bij 
pasgeborenen. In de toekomst zou vaccinatie tegen GBS, indien dit mogelijk zou 
worden, de meest effectieve vorm van preventie zijn, ook omdat het zowel early-
onset (pasgeborene wordt ziek in de eerste 7 dagen na de geboorte) als late-onset 
(pasgeborene wordt ziek na 7 dagen tot 3 maanden na de geboorte) GBS infecties zou 
voorkomen. Helaas is er nog geen effectief vaccin beschikbaar.
Voor de selectie van de beste richtlijn voor preventie van GBS infecties in Nederland is de 
kosteneffectiviteit en de incidentie van bewezen early-onset GBS sepsis van groot belang. 
Deze incidentie was 0.6 per 1000 levendgeborenen, lager dan verwacht en aanzienlijk 
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lager dan die in de VS, vóór de invoering van de CDC richtlijnen. Vanwege deze lage 
incidentie zal geen van de richtlijnen een redelijke kosteneffectiviteit kennen. 
Conclusie
Ons onderzoek beoogde de in 1999 in Nederland ingevoerde landelijke en op 
risicofactoren gebaseerde richtlijnen voor de preventie van neonatale early-onset GBS 
ziekte te evalueren om ze vervolgens verder te kunnen verbeteren. 
Binnen Europa vonden we een sterk uiteenlopende incidentie van GBS kolonisatie in de 
zwangerschap en van neonatale GBS ziekte. Slechts vier Europese landen kenden in 1999 
landelijke richtlijnen voor preventie. Na de invoering van de Nederlandse richtlijnen was 
er een bescheiden afname van het aantal gevallen van bewezen neonatale early-onset 
GBS sepsis. Hoewel de meeste gynaecologen bekend waren met de richtlijnen en er mee 
instemden, werden de richtlijnen dikwijls niet goed toegepast. Er trad geen verandering 
op in serotypische en genotypische eigenschappen van het micro-organisme, noch 
vond er een wijziging plaats in de gevoeligheid van de GBS stammen. Over het geheel 
genomen was het effect van de invoering van de Nederlandse richtlijn teleurstellend. 
Daarom is er nu een discussie gaande over het vervaardigen van de meest effectieve 
richtlijn voor preventie in de specifi eke Nederlandse situatie.
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Mijn promotor prof. dr. L.A.A. Kollée, beste Louis, inmiddels alweer tien jaar geleden 
vroeg je mij als arts-assistent op de afdeling neonatologie of ik een landelijk onderzoek 
wilde gaan doen naar het voorkomen van neonatale Groep B Streptococcen infectie. 
Dit onderzoek zou goed passen in het kader van het voor arts-assistenten verplichte 
wetenschappelijk onderzoek. Je gaf destijds al aan dat dit mogelijk zou kunnen uitgroeien 
tot een promotie-onderzoek, waarop ik je meteen meldde dat je daarvoor dan toch echt 
iemand anders zou moeten zoeken. Eenmaal aan het onderzoek begonnen raakte ik 
echter sterk betrokken bij het belang hiervan en wist je mij met je enthousiasme toch te 
overtuigen om het onderzoek verder uit te breiden tot dit promotieonderzoek. Uiteraard 
ben ik je daar zeer dankbaar voor. Ik ben ervan overtuigd dat jouw steun en positieve 
instelling -ook in moeilijke tijden toen het einde nog lang niet in zicht leek- onontbeerlijk 
zijn geweest om dit promotieonderzoek af te ronden.
Mijn promotor prof. dr. J.L. Kimpen, beste Jan, bij aanvang van het promotie-onderzoek 
heb je mij beloofd me te waarschuwen als het te lang zou gaan duren. Je hebt me er 
regelmatig op gewezen dat het in mijn belang was om door te zetten en het onderzoek 
zo snel mogelijk af te maken. Bedankt voor je nuchtere kijk op de zaken en je motto dat 
hard werken erbij hoort als je iets wil bereiken. 
Mijn co-promotor dr. L.J. Gerards, beste Leo, dank voor je gastvrijheid, ik zal de discussies 
die zijn gevoerd in jouw kamer in het WKZ missen (ook de koekjes). Ik heb veel van je 
geleerd, met name door de kritische wijze waarop je de artikelen hebt beoordeeld. 
Mijn co-promotor dr. A.H. Adriaanse, beste Albert, ondanks alles wat jij de afgelopen 
jaren hebt meegemaakt, ben je je altijd blijven inzetten voor de voortgang van mijn 
promotie-onderzoek. Ik realiseer me heel goed dat dit niet altijd makkelijk voor je is 
geweest.
Dr. P.C.M. Pasker-de Jong, beste Pieternel, ook jou wil ik bedanken dat je ondanks “alles” 
enthousiast bleef en mij bleef steunen. Dankbaar denk ik terug aan de vele uren die ik 
heb doorgebracht bij jou thuis.
Dr. R.A. van Lingen, beste Richard, voor mij was je regelmatig de rots in de branding, 
met name in moeilijke tijden bleef je mij steunen en wist jij als geen ander hoe moeilijk 
het kan zijn om aan je onderzoek te werken naast je werk als kinderarts in een perifeer 
ziekenhuis. 
Dr. G.A. de Jonge, beste Guus, als “nestor” van dit promotieonderzoek wil ik je in het 
bijzonder danken voor het feit dat jij destijds de anderen hebt overtuigd van het belang 
van dit onderzoek. Dank voor al die keren dat je naar Bussum bent gekomen, om weer 
één van de vele versies van een van de artikelen met me door te nemen. 
Prof. Dr. J.A.A. Hoogkamp-Korstanje, beste Mieke, bedankt voor je steun en kritische 
commentaar op met name het microbiologische deel van het proefschrift.
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Prof. dr. B.J. Kullberg, Prof. Dr. J.G. Nijhuis en Prof. Dr. J. van der Velden, leden van de 
manuscriptcommissie, ben ik dankbaar voor hun bereidheid om zitting te nemen in deze 
commissie en om mijn manuscript kritisch door te lezen. 
Beste collega’s, Lody, Tim, Norbert, Dianne, Anne-Marie en Judith, bedankt voor jullie 
begrip en de gelegenheid die jullie mij in de afgelopen vier jaar geboden hebben om dit 
proefschrift te kunnen afmaken.
Lieve Mama, bedankt voor het feit dat je samen met Papa mij hebt bijgebracht dat je met 
hard werken en doorzettingsvermogen veel kan bereiken. Ik weet zeker dat dit de reden 
is geweest dat ik dit proefschrift uiteindelijk heb kunnen afmaken.
Lieve Pa en Ma, dank voor jullie steun en vertrouwen in een uiteindelijk goede afl oop 
van deze promotie. Pa, heel erg bedankt dat je vandaag je plekje in de corona hebt 
willen opgeven om één van mijn paranimfen te kunnen zijn.
Lieve Anneke, oppas van Frans en Hugo, ik ben je dankbaar dat je er al die jaren voor 
hebt gezorgd dat het aan het thuisfront allemaal goed geregeld was.
Als laatste wil ik “mijn mannen” bedanken.
Lieve Frans en Hugo, door jullie blijf ik me inzetten voor de gezondheid van ieder kind 
en hoop ik nog heel veel kinderen beter te kunnen maken.
Lieve Frank, door jou blijf ik met beide benen op de grond staan. Je weet dat ik zonder 
jouw steun en begrip dit promotie-onderzoek nooit zou hebben afgemaakt. 
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haar eindexamen VWO aan het Eckartcollege in Eindhoven, waarna zij Geneeskunde 
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Radboud Universiteit). In 1991 behaalde zij haar doctoraal, in 1993 volgde het arts-
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werkzaam als kinderarts in het Flevoziekenhuis te Almere.
Monique is getrouwd met Frank, samen hebben zij twee zonen: Frans (1999) en Hugo (2000). 
